{
  "file_name": "CUAD_v1/full_contract_pdf\\Part_I\\Development\\CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement.pdf",
  "annotations": [
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Document Name_0",
      "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
      "answer_text": "LICENSE AND DEVELOPMENT AGREEMENT",
      "page_number": 0,
      "words": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ],
          "confidence": 0.9851366877555847
        }
      ],
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Coherus BioSciences, Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ],
          "confidence": 0.9984176158905029
        }
      ],
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Bioeq IP AG",
      "page_number": 0,
      "words": [
        {
          "text": "BIOEQ IP AG",
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ],
          "confidence": 0.998244047164917
        }
      ],
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Licensee",
      "page_number": 0,
      "words": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ],
          "confidence": 0.9851366877555847
        }
      ],
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Bioeq",
      "page_number": 0,
      "words": [
        {
          "text": "BIOEQ IP AG",
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ],
          "confidence": 0.998244047164917
        }
      ],
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Agreement Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
      "answer_text": "Nov. 02, 2019",
      "page_number": 0,
      "words": [
        {
          "text": "NOV 02, 2019",
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ],
          "confidence": 0.9989316463470459
        }
      ],
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Effective Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effectiveÂ ",
      "answer_text": "Nov. 02, 2019",
      "page_number": 0,
      "words": [
        {
          "text": "NOV 02, 2019",
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ],
          "confidence": 0.9989316463470459
        }
      ],
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Expiration Date_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "Except as otherwise specified in this Agreement, the Parties' respective rights and obligations under this Agreement shall commence on the Effective Date and shall remain in full force for ten (10) years after the First Commercial Sale of the first Licensed Product, and shall thereafter automatically renew for an unlimited period of time unless otherwise terminated in accordance with Section 15.2.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Expiration Date_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "Except as otherwise specified in this Agreement, the Parties' respective rights and obligations under this Agreement shall commence on the Effective Date and shall remain in full force for ten (10) years after the First Commercial Sale of the first Licensed Product, and shall thereafter automatically renew for an unlimited period of time unless otherwise terminated in accordance with Section 15.2.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Renewal Term_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Renewal Term\" that should be reviewed by a lawyer. Details: What is the renewal term after the initial term expires? This includes automatic extensions and unilateral extensions with prior notice.",
      "answer_text": "Except as otherwise specified in this Agreement, the Parties' respective rights and obligations under this Agreement shall commence on the Effective Date and shall remain in full force for ten (10) years after the First Commercial Sale of the first Licensed Product, and shall thereafter automatically renew for an unlimited period of time unless otherwise terminated in accordance with Section 15.2.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Renewal Term_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Renewal Term\" that should be reviewed by a lawyer. Details: What is the renewal term after the initial term expires? This includes automatic extensions and unilateral extensions with prior notice.",
      "answer_text": "Except as otherwise specified in this Agreement, the Parties' respective rights and obligations under this Agreement shall commence on the Effective Date and shall remain in full force for ten (10) years after the First Commercial Sale of the first Licensed Product, and shall thereafter automatically renew for an unlimited period of time unless otherwise terminated in accordance with Section 15.2.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Governing Law_2",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement shall be governed by and construed in accordance with the laws of [***], without regard to the conflicts of law principles thereof, and [***].",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Non-Compete_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "Upon the consummation of such definitive agreement, if Licensee has not then divested all such Competitive Products such that a Competitor Change of Control has occurred, Bioeq may, upon sending written notice to Licensee within sixty (60) days thereafter, terminate this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Non-Compete_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "Upon the consummation of such definitive agreement, if Licensee has not then divested all such Competitive Products such that a Competitor Change of Control has occurred, Bioeq may, upon sending written notice to Licensee within sixty (60) days thereafter, terminate this Agreement.",
      "page_number": 3,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9717634320259094
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.9994022250175476
        },
        {
          "text": "1.5",
          "bbox": [
            480.0,
            402.0,
            562.0,
            453.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "Biologics License Application or BLA means a request for permission to introduce, or deliver for introduction,",
          "bbox": [
            727.0,
            409.0,
            3025.0,
            453.0
          ],
          "confidence": 0.9921256899833679
        },
        {
          "text": "a biologic product into interstate commerce (21 CFR 601.2) to the FDA, including any supplements, addendums, or amendments",
          "bbox": [
            281.0,
            473.0,
            3025.0,
            517.0
          ],
          "confidence": 0.9932877421379089
        },
        {
          "text": "thereto. For the avoidance of doubt, the term Biologics License Application or BLA shall include any Abbreviated Biologics License",
          "bbox": [
            281.0,
            535.0,
            3025.0,
            579.0
          ],
          "confidence": 0.9936209917068481
        },
        {
          "text": "Application.",
          "bbox": [
            279.0,
            598.0,
            524.0,
            647.0
          ],
          "confidence": 0.9999745488166809
        },
        {
          "text": "1.6",
          "bbox": [
            480.0,
            711.0,
            562.0,
            762.0
          ],
          "confidence": 0.9999096989631653
        },
        {
          "text": "Biologics License Application Approval means issuance of a Department of Health and Human Services",
          "bbox": [
            723.0,
            713.0,
            3029.0,
            764.0
          ],
          "confidence": 0.9958980083465576
        },
        {
          "text": "U.S. License under 351(k) of the Public Health Services Act controlling the manufacture and sale of biologic products or any",
          "bbox": [
            277.0,
            775.0,
            3025.0,
            830.0
          ],
          "confidence": 0.9973142147064209
        },
        {
          "text": "successor statutory provisions thereof..",
          "bbox": [
            275.0,
            842.0,
            1066.0,
            890.0
          ],
          "confidence": 0.9804762005805969
        },
        {
          "text": "1.7",
          "bbox": [
            480.0,
            958.0,
            562.0,
            1009.0
          ],
          "confidence": 0.9998540878295898
        },
        {
          "text": "BPCIA means the Biologics Price Competition and Innovation Act of 2009, as amended..",
          "bbox": [
            723.0,
            958.0,
            2539.0,
            1009.0
          ],
          "confidence": 0.9839229583740234
        },
        {
          "text": "1.8",
          "bbox": [
            478.0,
            1073.0,
            562.0,
            1124.0
          ],
          "confidence": 0.999962329864502
        },
        {
          "text": "CMO means contract manufacturing organization.",
          "bbox": [
            723.0,
            1073.0,
            1749.0,
            1126.0
          ],
          "confidence": 0.9971001744270325
        },
        {
          "text": "1.9",
          "bbox": [
            478.0,
            1191.0,
            560.0,
            1243.0
          ],
          "confidence": 0.9999006390571594
        },
        {
          "text": "Commercially Reasonable Efforts means, with respect to the efforts to be used by a Party under this",
          "bbox": [
            725.0,
            1195.0,
            3023.0,
            1241.0
          ],
          "confidence": 0.997243344783783
        },
        {
          "text": "Agreement with respect to the Licensed Products, those efforts and resources normally used by a major pharmaceutical or a",
          "bbox": [
            283.0,
            1263.0,
            3025.0,
            1307.0
          ],
          "confidence": 0.9916821718215942
        },
        {
          "text": "sufficiently financed biotechnology company for a product owned by it, or to which it has rights, which is of similar market potential at",
          "bbox": [
            277.0,
            1321.0,
            3029.0,
            1372.0
          ],
          "confidence": 0.9948831796646118
        },
        {
          "text": "comparable stages of development, taking into account the competitiveness of the marketplace, the proprietary position of the product.",
          "bbox": [
            281.0,
            1389.0,
            3023.0,
            1433.0
          ],
          "confidence": 0.9958548545837402
        },
        {
          "text": "the performance of other products that are of similar market potential and the likely timing of other product's entry into the market,",
          "bbox": [
            281.0,
            1453.0,
            3023.0,
            1497.0
          ],
          "confidence": 0.9958077073097229
        },
        {
          "text": "the regulatory structure involved, the profitability of the applicable product, relevant Third Party intellectual property necessary to",
          "bbox": [
            281.0,
            1515.0,
            3025.0,
            1559.0
          ],
          "confidence": 0.9959139227867126
        },
        {
          "text": "manufacture or Commercialize the Licensed Product and other relevant factors commonly considered in similar circumstances,",
          "bbox": [
            275.0,
            1571.0,
            3029.0,
            1625.0
          ],
          "confidence": 0.995061457157135
        },
        {
          "text": "including technical, legal, scientific or medical factors.",
          "bbox": [
            281.0,
            1641.0,
            1372.0,
            1685.0
          ],
          "confidence": 0.9983561038970947
        },
        {
          "text": "1.10",
          "bbox": [
            480.0,
            1754.0,
            589.0,
            1802.0
          ],
          "confidence": 0.9999697208404541
        },
        {
          "text": "Commercialization means the conduct of all activities undertaken before and after Regulatory Approval.",
          "bbox": [
            750.0,
            1754.0,
            3029.0,
            1805.0
          ],
          "confidence": 0.9943490624427795
        },
        {
          "text": "relating to the promotion, marketing, sale and distribution (including importing, exporting, transporting, customs clearance, warehousing,",
          "bbox": [
            275.0,
            1820.0,
            3025.0,
            1873.0
          ],
          "confidence": 0.9991621971130371
        },
        {
          "text": "invoicing, handling and delivering products to customers) of pharmaceutical products, including: (a) sales force efforts, detailing,",
          "bbox": [
            277.0,
            1882.0,
            3023.0,
            1935.0
          ],
          "confidence": 0.989540696144104
        },
        {
          "text": "advertising, medical education, planning, marketing, sales force training and sales and distribution; and (b) scientific and medical",
          "bbox": [
            281.0,
            1950.0,
            3029.0,
            1994.0
          ],
          "confidence": 0.9934641718864441
        },
        {
          "text": "affairs. For clarity, Commercialization does not include any Development activities, whether conducted before or after Regulatory.",
          "bbox": [
            275.0,
            2005.0,
            3025.0,
            2063.0
          ],
          "confidence": 0.991479754447937
        },
        {
          "text": "Approval. \"Commercialize\"' and \"Commercializing\"' have correlative meanings..",
          "bbox": [
            279.0,
            2076.0,
            1956.0,
            2127.0
          ],
          "confidence": 0.9811223745346069
        },
        {
          "text": "1.11",
          "bbox": [
            480.0,
            2189.0,
            582.0,
            2237.0
          ],
          "confidence": 0.9999496936798096
        },
        {
          "text": "Competitive Product means (i) any product which contains Ranibizumab and is either a Reference Product or",
          "bbox": [
            752.0,
            2195.0,
            3027.0,
            2238.0
          ],
          "confidence": 0.9990459084510803
        },
        {
          "text": "a biosimilar to a Reference Product, but excluding in any case the Licensed Products, (ii) [***] (but for clarity [***]) or (iii) [***] (but",
          "bbox": [
            277.0,
            2255.0,
            3029.0,
            2304.0
          ],
          "confidence": 0.988621175289154
        },
        {
          "text": "for clarity [***])",
          "bbox": [
            279.0,
            2319.0,
            625.0,
            2368.0
          ],
          "confidence": 0.9934876561164856
        },
        {
          "text": "1.12",
          "bbox": [
            478.0,
            2430.0,
            587.0,
            2483.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Competitor means any person or entity (other than the Parties and their Affiliates) which has initiated and is",
          "bbox": [
            750.0,
            2438.0,
            3027.0,
            2487.0
          ],
          "confidence": 0.9882062673568726
        },
        {
          "text": "then-active in [***] the marketing, selling or distribution of a Competitive Product, [***] in the Territory, as well as any Affiliate of",
          "bbox": [
            279.0,
            2500.0,
            3032.0,
            2549.0
          ],
          "confidence": 0.9960110783576965
        },
        {
          "text": "any such person or entity..",
          "bbox": [
            283.0,
            2567.0,
            798.0,
            2611.0
          ],
          "confidence": 0.9808448553085327
        },
        {
          "text": "1.13",
          "bbox": [
            477.0,
            2675.0,
            587.0,
            2728.0
          ],
          "confidence": 0.9999721050262451
        },
        {
          "text": "Competitor Change of Control means any of the following events after the Effective Date:.",
          "bbox": [
            752.0,
            2681.0,
            2644.0,
            2732.0
          ],
          "confidence": 0.9916378259658813
        },
        {
          "text": "(a)",
          "bbox": [
            480.0,
            2794.0,
            547.0,
            2847.0
          ],
          "confidence": 0.9996528625488281
        },
        {
          "text": "any Competitor (i) becomes the beneficial owner, directly or indirectly, of shares of capital stock or other.",
          "bbox": [
            868.0,
            2794.0,
            3023.0,
            2842.0
          ],
          "confidence": 0.9901131391525269
        },
        {
          "text": "interests (including partnership interests) of the Licensee then outstanding and normally entitled (without regard to the occurrence of",
          "bbox": [
            279.0,
            2858.0,
            3032.0,
            2905.0
          ],
          "confidence": 0.9926522970199585
        },
        {
          "text": "representing more than fifty percent (50%) of the total voting power of all outstanding classes of Voting Stock of the Licensee or (ii)",
          "bbox": [
            274.0,
            2988.0,
            3023.0,
            3039.0
          ],
          "confidence": 0.9979057908058167
        },
        {
          "text": "of the Licensee's board of directors, supervisory board or similar governing body (Board of Directors); or.",
          "bbox": [
            279.0,
            3119.0,
            2460.0,
            3165.0
          ],
          "confidence": 0.9923440217971802
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4435.0,
            1437.0,
            4477.0
          ],
          "confidence": 0.991787850856781
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Non-Compete_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "Bioeq may terminate this Agreement immediately upon written notice to Licensee, if Licensee conducts any clinical development of, markets, sells or distributes any Competitive Product in the Territory, whether directly or indirectly through the intermediary of a Third Party or its Affiliates (Restricted Activities);",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Non-Compete_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "Bioeq may terminate this Agreement immediately upon written notice to Licensee, if Licensee conducts any clinical development of, markets, sells or distributes any Competitive Product in the Territory, whether directly or indirectly through the intermediary of a Third Party or its Affiliates (Restricted Activities);",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Non-Compete_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "During the term of this Agreement, neither Party shall, and shall not permit its Affiliates to, nor grant any rights to any Third Party to, directly or indirectly, Commercialize, or Develop any New Product for Commercialization in the Territory, except as permitted in accordance with this Section 3.4.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Non-Compete_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "During the term of this Agreement, neither Party shall, and shall not permit its Affiliates to, nor grant any rights to any Third Party to, directly or indirectly, Commercialize, or Develop any New Product for Commercialization in the Territory, except as permitted in accordance with this Section 3.4.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Exclusivity_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Solely in the event that this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9 or by Licensee pursuant to Section 15.2.5 , Licensee shall grant, and hereby grants to Bioeq an exclusive, royalty-free, fully paid, sublicenseable, license to use the Licensee-Controlled Trademarks which were actually used by Licensee to Commercialize the Licensed Products in the Territory in connection with Bioeq's Commercialization of the Licensed Products in the Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.29",
          "bbox": [
            2775.0,
            283.0,
            3027.0,
            325.0
          ],
          "confidence": 0.9998047947883606
        },
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            344.0,
            3030.0,
            382.0
          ],
          "confidence": 0.999879777431488
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            404.0,
            3027.0,
            440.0
          ],
          "confidence": 0.999829888343811
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not",
          "bbox": [
            321.0,
            460.0,
            2991.0,
            503.0
          ],
          "confidence": 0.9897100329399109
        },
        {
          "text": "material and would likely cause competitive harm to the registrant if publicly disclosed.",
          "bbox": [
            825.0,
            515.0,
            2478.0,
            559.0
          ],
          "confidence": 0.9881774187088013
        },
        {
          "text": "NOV 02, 2019",
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ],
          "confidence": 0.9989316463470459
        },
        {
          "text": "BIOEQ IP AG",
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ],
          "confidence": 0.998244047164917
        },
        {
          "text": "AND",
          "bbox": [
            1595.0,
            1986.0,
            1715.0,
            2034.0
          ],
          "confidence": 0.9988322257995605
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ],
          "confidence": 0.9984176158905029
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ],
          "confidence": 0.9851366877555847
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9914476871490479
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Solely in the event that this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9 or by Licensee pursuant to Section 15.2.5 , Licensee shall grant, and hereby grants to Bioeq an exclusive, royalty-free, fully paid, sublicenseable, license to use the Licensee-Controlled Trademarks which were actually used by Licensee to Commercialize the Licensed Products in the Territory in connection with Bioeq's Commercialization of the Licensed Products in the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Subject to the provisions of this Agreement, Bioeq hereby grants to Licensee an exclusive (even as to Bioeq), milestone- and royalty-bearing, non-transferable license (including the right to grant sublicenses only to the extent permitted by Section 2.1.2) under the Licensed Technology (including the Licensed Patents) to use, sell, have sold, import, have imported or otherwise Commercialize the Licensed Products in the Field in the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Exclusivity_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Subject to the provisions of this Agreement, Bioeq hereby grants to Licensee an exclusive (even as to Bioeq), milestone- and royalty-bearing, non-transferable license (including the right to grant sublicenses only to the extent permitted by Section 2.1.2) under the Licensed Technology (including the Licensed Patents) to use, sell, have sold, import, have imported or otherwise Commercialize the Licensed Products in the Field in the Territory.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "For clarity, the exclusive license granted to Licensee pursuant to Section 2.1 shall extend to all Intellectual Property Rights and Know-How Controlled by Bioeq and embodied within, or claiming or covering the Bioeq Improvements.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Exclusivity_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "For clarity, the exclusive license granted to Licensee pursuant to Section 2.1 shall extend to all Intellectual Property Rights and Know-How Controlled by Bioeq and embodied within, or claiming or covering the Bioeq Improvements.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__No-Solicit Of Employees_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Employees\" that should be reviewed by a lawyer. Details: Is there a restriction on a partyâs soliciting or hiring employees and/or contractors from theÂ  counterparty, whether during the contract or after the contract ends (or both)?",
      "answer_text": "Each Party agrees that, during the [***] ([***]) [***] period starting from the Effective Date, such Party will not, directly or indirectly, solicit for employment any employee of the other Party or its Affiliates or otherwise induce or attempt to induce such employees to terminate their employment with such other Party or such other Party's Affiliates; provided, however, that general public solicitations and advertisements not directed at employees of the other Party, and the extension of offers to persons who respond to such general solicitations and advertisements, will not be deemed violations of this provision.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__No-Solicit Of Employees_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Employees\" that should be reviewed by a lawyer. Details: Is there a restriction on a partyâs soliciting or hiring employees and/or contractors from theÂ  counterparty, whether during the contract or after the contract ends (or both)?",
      "answer_text": "Each Party agrees that, during the [***] ([***]) [***] period starting from the Effective Date, such Party will not, directly or indirectly, solicit for employment any employee of the other Party or its Affiliates or otherwise induce or attempt to induce such employees to terminate their employment with such other Party or such other Party's Affiliates; provided, however, that general public solicitations and advertisements not directed at employees of the other Party, and the extension of offers to persons who respond to such general solicitations and advertisements, will not be deemed violations of this provision.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Termination For Convenience_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate thisÂ  contract without cause (solely by giving a notice and allowing a waitingÂ  period to expire)?",
      "answer_text": "Licensee may terminate this Agreement for convenience upon eighteen (18) months' advance written notice to Bioeq; provided, however, that any such termination for convenience shall not become effective prior to twelve (12) months after the First Commercial Sale of the first Licensed Product.",
      "page_number": 3,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9717634320259094
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.9994022250175476
        },
        {
          "text": "1.5",
          "bbox": [
            480.0,
            402.0,
            562.0,
            453.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "Biologics License Application or BLA means a request for permission to introduce, or deliver for introduction,",
          "bbox": [
            727.0,
            409.0,
            3025.0,
            453.0
          ],
          "confidence": 0.9921256899833679
        },
        {
          "text": "a biologic product into interstate commerce (21 CFR 601.2) to the FDA, including any supplements, addendums, or amendments",
          "bbox": [
            281.0,
            473.0,
            3025.0,
            517.0
          ],
          "confidence": 0.9932877421379089
        },
        {
          "text": "thereto. For the avoidance of doubt, the term Biologics License Application or BLA shall include any Abbreviated Biologics License",
          "bbox": [
            281.0,
            535.0,
            3025.0,
            579.0
          ],
          "confidence": 0.9936209917068481
        },
        {
          "text": "Application.",
          "bbox": [
            279.0,
            598.0,
            524.0,
            647.0
          ],
          "confidence": 0.9999745488166809
        },
        {
          "text": "1.6",
          "bbox": [
            480.0,
            711.0,
            562.0,
            762.0
          ],
          "confidence": 0.9999096989631653
        },
        {
          "text": "Biologics License Application Approval means issuance of a Department of Health and Human Services",
          "bbox": [
            723.0,
            713.0,
            3029.0,
            764.0
          ],
          "confidence": 0.9958980083465576
        },
        {
          "text": "U.S. License under 351(k) of the Public Health Services Act controlling the manufacture and sale of biologic products or any",
          "bbox": [
            277.0,
            775.0,
            3025.0,
            830.0
          ],
          "confidence": 0.9973142147064209
        },
        {
          "text": "successor statutory provisions thereof..",
          "bbox": [
            275.0,
            842.0,
            1066.0,
            890.0
          ],
          "confidence": 0.9804762005805969
        },
        {
          "text": "1.7",
          "bbox": [
            480.0,
            958.0,
            562.0,
            1009.0
          ],
          "confidence": 0.9998540878295898
        },
        {
          "text": "BPCIA means the Biologics Price Competition and Innovation Act of 2009, as amended..",
          "bbox": [
            723.0,
            958.0,
            2539.0,
            1009.0
          ],
          "confidence": 0.9839229583740234
        },
        {
          "text": "1.8",
          "bbox": [
            478.0,
            1073.0,
            562.0,
            1124.0
          ],
          "confidence": 0.999962329864502
        },
        {
          "text": "CMO means contract manufacturing organization.",
          "bbox": [
            723.0,
            1073.0,
            1749.0,
            1126.0
          ],
          "confidence": 0.9971001744270325
        },
        {
          "text": "1.9",
          "bbox": [
            478.0,
            1191.0,
            560.0,
            1243.0
          ],
          "confidence": 0.9999006390571594
        },
        {
          "text": "Commercially Reasonable Efforts means, with respect to the efforts to be used by a Party under this",
          "bbox": [
            725.0,
            1195.0,
            3023.0,
            1241.0
          ],
          "confidence": 0.997243344783783
        },
        {
          "text": "Agreement with respect to the Licensed Products, those efforts and resources normally used by a major pharmaceutical or a",
          "bbox": [
            283.0,
            1263.0,
            3025.0,
            1307.0
          ],
          "confidence": 0.9916821718215942
        },
        {
          "text": "sufficiently financed biotechnology company for a product owned by it, or to which it has rights, which is of similar market potential at",
          "bbox": [
            277.0,
            1321.0,
            3029.0,
            1372.0
          ],
          "confidence": 0.9948831796646118
        },
        {
          "text": "comparable stages of development, taking into account the competitiveness of the marketplace, the proprietary position of the product.",
          "bbox": [
            281.0,
            1389.0,
            3023.0,
            1433.0
          ],
          "confidence": 0.9958548545837402
        },
        {
          "text": "the performance of other products that are of similar market potential and the likely timing of other product's entry into the market,",
          "bbox": [
            281.0,
            1453.0,
            3023.0,
            1497.0
          ],
          "confidence": 0.9958077073097229
        },
        {
          "text": "the regulatory structure involved, the profitability of the applicable product, relevant Third Party intellectual property necessary to",
          "bbox": [
            281.0,
            1515.0,
            3025.0,
            1559.0
          ],
          "confidence": 0.9959139227867126
        },
        {
          "text": "manufacture or Commercialize the Licensed Product and other relevant factors commonly considered in similar circumstances,",
          "bbox": [
            275.0,
            1571.0,
            3029.0,
            1625.0
          ],
          "confidence": 0.995061457157135
        },
        {
          "text": "including technical, legal, scientific or medical factors.",
          "bbox": [
            281.0,
            1641.0,
            1372.0,
            1685.0
          ],
          "confidence": 0.9983561038970947
        },
        {
          "text": "1.10",
          "bbox": [
            480.0,
            1754.0,
            589.0,
            1802.0
          ],
          "confidence": 0.9999697208404541
        },
        {
          "text": "Commercialization means the conduct of all activities undertaken before and after Regulatory Approval.",
          "bbox": [
            750.0,
            1754.0,
            3029.0,
            1805.0
          ],
          "confidence": 0.9943490624427795
        },
        {
          "text": "relating to the promotion, marketing, sale and distribution (including importing, exporting, transporting, customs clearance, warehousing,",
          "bbox": [
            275.0,
            1820.0,
            3025.0,
            1873.0
          ],
          "confidence": 0.9991621971130371
        },
        {
          "text": "invoicing, handling and delivering products to customers) of pharmaceutical products, including: (a) sales force efforts, detailing,",
          "bbox": [
            277.0,
            1882.0,
            3023.0,
            1935.0
          ],
          "confidence": 0.989540696144104
        },
        {
          "text": "advertising, medical education, planning, marketing, sales force training and sales and distribution; and (b) scientific and medical",
          "bbox": [
            281.0,
            1950.0,
            3029.0,
            1994.0
          ],
          "confidence": 0.9934641718864441
        },
        {
          "text": "affairs. For clarity, Commercialization does not include any Development activities, whether conducted before or after Regulatory.",
          "bbox": [
            275.0,
            2005.0,
            3025.0,
            2063.0
          ],
          "confidence": 0.991479754447937
        },
        {
          "text": "Approval. \"Commercialize\"' and \"Commercializing\"' have correlative meanings..",
          "bbox": [
            279.0,
            2076.0,
            1956.0,
            2127.0
          ],
          "confidence": 0.9811223745346069
        },
        {
          "text": "1.11",
          "bbox": [
            480.0,
            2189.0,
            582.0,
            2237.0
          ],
          "confidence": 0.9999496936798096
        },
        {
          "text": "Competitive Product means (i) any product which contains Ranibizumab and is either a Reference Product or",
          "bbox": [
            752.0,
            2195.0,
            3027.0,
            2238.0
          ],
          "confidence": 0.9990459084510803
        },
        {
          "text": "a biosimilar to a Reference Product, but excluding in any case the Licensed Products, (ii) [***] (but for clarity [***]) or (iii) [***] (but",
          "bbox": [
            277.0,
            2255.0,
            3029.0,
            2304.0
          ],
          "confidence": 0.988621175289154
        },
        {
          "text": "for clarity [***])",
          "bbox": [
            279.0,
            2319.0,
            625.0,
            2368.0
          ],
          "confidence": 0.9934876561164856
        },
        {
          "text": "1.12",
          "bbox": [
            478.0,
            2430.0,
            587.0,
            2483.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Competitor means any person or entity (other than the Parties and their Affiliates) which has initiated and is",
          "bbox": [
            750.0,
            2438.0,
            3027.0,
            2487.0
          ],
          "confidence": 0.9882062673568726
        },
        {
          "text": "then-active in [***] the marketing, selling or distribution of a Competitive Product, [***] in the Territory, as well as any Affiliate of",
          "bbox": [
            279.0,
            2500.0,
            3032.0,
            2549.0
          ],
          "confidence": 0.9960110783576965
        },
        {
          "text": "any such person or entity..",
          "bbox": [
            283.0,
            2567.0,
            798.0,
            2611.0
          ],
          "confidence": 0.9808448553085327
        },
        {
          "text": "1.13",
          "bbox": [
            477.0,
            2675.0,
            587.0,
            2728.0
          ],
          "confidence": 0.9999721050262451
        },
        {
          "text": "Competitor Change of Control means any of the following events after the Effective Date:.",
          "bbox": [
            752.0,
            2681.0,
            2644.0,
            2732.0
          ],
          "confidence": 0.9916378259658813
        },
        {
          "text": "(a)",
          "bbox": [
            480.0,
            2794.0,
            547.0,
            2847.0
          ],
          "confidence": 0.9996528625488281
        },
        {
          "text": "any Competitor (i) becomes the beneficial owner, directly or indirectly, of shares of capital stock or other.",
          "bbox": [
            868.0,
            2794.0,
            3023.0,
            2842.0
          ],
          "confidence": 0.9901131391525269
        },
        {
          "text": "interests (including partnership interests) of the Licensee then outstanding and normally entitled (without regard to the occurrence of",
          "bbox": [
            279.0,
            2858.0,
            3032.0,
            2905.0
          ],
          "confidence": 0.9926522970199585
        },
        {
          "text": "representing more than fifty percent (50%) of the total voting power of all outstanding classes of Voting Stock of the Licensee or (ii)",
          "bbox": [
            274.0,
            2988.0,
            3023.0,
            3039.0
          ],
          "confidence": 0.9979057908058167
        },
        {
          "text": "of the Licensee's board of directors, supervisory board or similar governing body (Board of Directors); or.",
          "bbox": [
            279.0,
            3119.0,
            2460.0,
            3165.0
          ],
          "confidence": 0.9923440217971802
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4435.0,
            1437.0,
            4477.0
          ],
          "confidence": 0.991787850856781
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Termination For Convenience_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate thisÂ  contract without cause (solely by giving a notice and allowing a waitingÂ  period to expire)?",
      "answer_text": "Licensee may terminate this Agreement for convenience upon eighteen (18) months' advance written notice to Bioeq; provided, however, that any such termination for convenience shall not become effective prior to twelve (12) months after the First Commercial Sale of the first Licensed Product.",
      "page_number": 4,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9777219891548157
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3025.0,
            384.0
          ],
          "confidence": 0.9990074038505554
        },
        {
          "text": "(b)",
          "bbox": [
            486.0,
            406.0,
            542.0,
            451.0
          ],
          "confidence": 0.9973199963569641
        },
        {
          "text": "the Licensee enters into a merger, consolidation or similar transaction with a Competitor (whether or not.",
          "bbox": [
            870.0,
            402.0,
            3025.0,
            450.0
          ],
          "confidence": 0.9922320246696472
        },
        {
          "text": "such Party is the surviving entity) and as a result of such merger, consolidation or similar transaction (i) the managing directors or the.",
          "bbox": [
            281.0,
            470.0,
            3027.0,
            513.0
          ],
          "confidence": 0.9920163750648499
        },
        {
          "text": "members of the Board of Directors of the Licensee immediately prior to such transaction constitute less than a majority of the",
          "bbox": [
            277.0,
            530.0,
            3025.0,
            576.0
          ],
          "confidence": 0.9923511743545532
        },
        {
          "text": "managing directors or the members of the Board of Directors of the Licensee or such surviving person immediately following such",
          "bbox": [
            277.0,
            594.0,
            3027.0,
            643.0
          ],
          "confidence": 0.9862891435623169
        },
        {
          "text": "transaction or (ii) the persons that beneficially owned, directly or indirectly, the shares of Voting Stock of the Licensee immediately",
          "bbox": [
            277.0,
            656.0,
            3023.0,
            704.0
          ],
          "confidence": 0.9987921714782715
        },
        {
          "text": "prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of the Licensee representing a",
          "bbox": [
            275.0,
            718.0,
            3031.0,
            769.0
          ],
          "confidence": 0.9947993159294128
        },
        {
          "text": "majority of the total voting power of all outstanding classes of Voting Stock of the surviving person in substantially the same",
          "bbox": [
            279.0,
            786.0,
            3027.0,
            830.0
          ],
          "confidence": 0.9937988519668579
        },
        {
          "text": "proportions as their ownership of Voting Stock of the Licensee immediately prior to such transaction.",
          "bbox": [
            277.0,
            844.0,
            2342.0,
            895.0
          ],
          "confidence": 0.9985789060592651
        },
        {
          "text": "1.14",
          "bbox": [
            480.0,
            961.0,
            589.0,
            1009.0
          ],
          "confidence": 0.9999711513519287
        },
        {
          "text": "Confidential Information means, with respect to a Party, all Know-How and all other proprietary information.",
          "bbox": [
            754.0,
            967.0,
            3025.0,
            1011.0
          ],
          "confidence": 0.9920302629470825
        },
        {
          "text": "of such Party, including information on the business, affairs, research and development activities, results of non-clinical and clinical.",
          "bbox": [
            281.0,
            1031.0,
            3027.0,
            1074.0
          ],
          "confidence": 0.989547848701477
        },
        {
          "text": "trials, national and multinational regulatory proceedings and affairs, finances, plans, contractual relationships and operations of such.",
          "bbox": [
            281.0,
            1095.0,
            3025.0,
            1138.0
          ],
          "confidence": 0.9868026971817017
        },
        {
          "text": "Party. Furthermore, the terms and conditions of this Agreement shall be considered Confidential Information of both Parties. For the",
          "bbox": [
            281.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9930081367492676
        },
        {
          "text": "avoidance of doubt, all Know-How and proprietary information relating to the Licensed Products generated by or on behalf of Bioeq.",
          "bbox": [
            277.0,
            1217.0,
            3027.0,
            1265.0
          ],
          "confidence": 0.989470362663269
        },
        {
          "text": "and provided to Licensee hereunder shall be considered Confidential Information of Bioeq.",
          "bbox": [
            279.0,
            1277.0,
            2128.0,
            1330.0
          ],
          "confidence": 0.9949022531509399
        },
        {
          "text": "1.15",
          "bbox": [
            480.0,
            1396.0,
            589.0,
            1444.0
          ],
          "confidence": 0.9999708533287048
        },
        {
          "text": "Control (whether used as a noun or as a verb) or Controlled means, with respect to any Intellectual Property",
          "bbox": [
            752.0,
            1396.0,
            3025.0,
            1451.0
          ],
          "confidence": 0.9984130859375
        },
        {
          "text": "Right, Trademark or Know-How, the possession (whether by ownership or license, other than pursuant to this Agreement) by a Party",
          "bbox": [
            277.0,
            1462.0,
            3023.0,
            1513.0
          ],
          "confidence": 0.9943523406982422
        },
        {
          "text": "of the ability to grant to the other Party access or a license as provided herein under such Intellectual Property Right, Trademark or",
          "bbox": [
            281.0,
            1529.0,
            3027.0,
            1573.0
          ],
          "confidence": 0.9949034452438354
        },
        {
          "text": "Know-How without violating the terms of any agreement or other arrangements with any Third Party.",
          "bbox": [
            279.0,
            1590.0,
            2369.0,
            1637.0
          ],
          "confidence": 0.9864059686660767
        },
        {
          "text": "1.16",
          "bbox": [
            478.0,
            1698.0,
            591.0,
            1752.0
          ],
          "confidence": 0.9999558925628662
        },
        {
          "text": "Damages shall have the meaning ascribed to it in Section 9.4.3..",
          "bbox": [
            750.0,
            1701.0,
            2059.0,
            1752.0
          ],
          "confidence": 0.9965372681617737
        },
        {
          "text": "1.17",
          "bbox": [
            478.0,
            1818.0,
            591.0,
            1871.0
          ],
          "confidence": 0.9999223351478577
        },
        {
          "text": "Defend or Defense shall have the meaning ascribed to it in Section 9.4.2..",
          "bbox": [
            750.0,
            1820.0,
            2258.0,
            1871.0
          ],
          "confidence": 0.9893102049827576
        },
        {
          "text": "1.18",
          "bbox": [
            478.0,
            1937.0,
            591.0,
            1990.0
          ],
          "confidence": 0.9999673366546631
        },
        {
          "text": "Development means all non-clinical and clinical research and drug development activities as well as.",
          "bbox": [
            754.0,
            1944.0,
            3025.0,
            1988.0
          ],
          "confidence": 0.9888492822647095
        },
        {
          "text": "Manufacturing process development, upscaling of the Manufacturing process and chemistry, manufacturing and control development",
          "bbox": [
            279.0,
            2006.0,
            3027.0,
            2052.0
          ],
          "confidence": 0.9937490820884705
        },
        {
          "text": "work conducted in respect of any pharmaceutical product, including those necessary to obtain Regulatory Approval for such",
          "bbox": [
            281.0,
            2072.0,
            3027.0,
            2116.0
          ],
          "confidence": 0.9899325370788574
        },
        {
          "text": "pharmaceutical product. When used as a verb, Develop means to engage in Development.",
          "bbox": [
            279.0,
            2134.0,
            2148.0,
            2186.0
          ],
          "confidence": 0.9984303712844849
        },
        {
          "text": "1.19",
          "bbox": [
            478.0,
            2246.0,
            589.0,
            2299.0
          ],
          "confidence": 0.9999583959579468
        },
        {
          "text": "Disclosing Party shall have the meaning ascribed to it in Section 11.1.",
          "bbox": [
            752.0,
            2251.0,
            2195.0,
            2301.0
          ],
          "confidence": 0.9872499704360962
        },
        {
          "text": "1.20",
          "bbox": [
            478.0,
            2366.0,
            585.0,
            2414.0
          ],
          "confidence": 0.9999449253082275
        },
        {
          "text": "Effective Date shall have the meaning ascribed to it in the introductory paragraph above",
          "bbox": [
            752.0,
            2368.0,
            2572.0,
            2418.0
          ],
          "confidence": 0.9994855523109436
        },
        {
          "text": "1.21",
          "bbox": [
            478.0,
            2485.0,
            587.0,
            2538.0
          ],
          "confidence": 0.9999347925186157
        },
        {
          "text": "Existing Reference Product shall have the meaning ascribed to it in Section 1.61..",
          "bbox": [
            750.0,
            2487.0,
            2443.0,
            2538.0
          ],
          "confidence": 0.9832090735435486
        },
        {
          "text": "1.22",
          "bbox": [
            478.0,
            2600.0,
            589.0,
            2653.0
          ],
          "confidence": 0.9999254941940308
        },
        {
          "text": "FDA means the United States Food and Drug Administration, and any successor agency thereto",
          "bbox": [
            750.0,
            2602.0,
            2737.0,
            2655.0
          ],
          "confidence": 0.991290807723999
        },
        {
          "text": "1.23",
          "bbox": [
            480.0,
            2721.0,
            587.0,
            2768.0
          ],
          "confidence": 0.9999662041664124
        },
        {
          "text": "Field means any human use of the Licensed Product in the field of ophthalmology and for any other approved",
          "bbox": [
            749.0,
            2719.0,
            3029.0,
            2778.0
          ],
          "confidence": 0.9872778654098511
        },
        {
          "text": "labelled indication of such Licensed Products..",
          "bbox": [
            281.0,
            2789.0,
            1209.0,
            2831.0
          ],
          "confidence": 0.9907771944999695
        },
        {
          "text": "1.24",
          "bbox": [
            478.0,
            2900.0,
            589.0,
            2955.0
          ],
          "confidence": 0.9999393224716187
        },
        {
          "text": "First Commercial Sale means, with respect to any Licensed Product in the Territory, the first sale by",
          "bbox": [
            750.0,
            2904.0,
            3025.0,
            2957.0
          ],
          "confidence": 0.9871525764465332
        },
        {
          "text": "Licensee or its Affiliates of such Licensed Product to a Third Party for use in the Field in the Territory, after such Licensed Product.",
          "bbox": [
            277.0,
            2969.0,
            3027.0,
            3015.0
          ],
          "confidence": 0.9941776394844055
        },
        {
          "text": "has been granted Regulatory Approval for use in the Field in the Territory..",
          "bbox": [
            277.0,
            3033.0,
            1793.0,
            3083.0
          ],
          "confidence": 0.9928413033485413
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9924864768981934
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Change Of Control_3",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Licensee shall notify Bioeq in writing within [***] ([***]) days after entry by Licensee into a definitive agreement which would result in a Competitor Change of Control.",
      "page_number": 3,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9717634320259094
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.9994022250175476
        },
        {
          "text": "1.5",
          "bbox": [
            480.0,
            402.0,
            562.0,
            453.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "Biologics License Application or BLA means a request for permission to introduce, or deliver for introduction,",
          "bbox": [
            727.0,
            409.0,
            3025.0,
            453.0
          ],
          "confidence": 0.9921256899833679
        },
        {
          "text": "a biologic product into interstate commerce (21 CFR 601.2) to the FDA, including any supplements, addendums, or amendments",
          "bbox": [
            281.0,
            473.0,
            3025.0,
            517.0
          ],
          "confidence": 0.9932877421379089
        },
        {
          "text": "thereto. For the avoidance of doubt, the term Biologics License Application or BLA shall include any Abbreviated Biologics License",
          "bbox": [
            281.0,
            535.0,
            3025.0,
            579.0
          ],
          "confidence": 0.9936209917068481
        },
        {
          "text": "Application.",
          "bbox": [
            279.0,
            598.0,
            524.0,
            647.0
          ],
          "confidence": 0.9999745488166809
        },
        {
          "text": "1.6",
          "bbox": [
            480.0,
            711.0,
            562.0,
            762.0
          ],
          "confidence": 0.9999096989631653
        },
        {
          "text": "Biologics License Application Approval means issuance of a Department of Health and Human Services",
          "bbox": [
            723.0,
            713.0,
            3029.0,
            764.0
          ],
          "confidence": 0.9958980083465576
        },
        {
          "text": "U.S. License under 351(k) of the Public Health Services Act controlling the manufacture and sale of biologic products or any",
          "bbox": [
            277.0,
            775.0,
            3025.0,
            830.0
          ],
          "confidence": 0.9973142147064209
        },
        {
          "text": "successor statutory provisions thereof..",
          "bbox": [
            275.0,
            842.0,
            1066.0,
            890.0
          ],
          "confidence": 0.9804762005805969
        },
        {
          "text": "1.7",
          "bbox": [
            480.0,
            958.0,
            562.0,
            1009.0
          ],
          "confidence": 0.9998540878295898
        },
        {
          "text": "BPCIA means the Biologics Price Competition and Innovation Act of 2009, as amended..",
          "bbox": [
            723.0,
            958.0,
            2539.0,
            1009.0
          ],
          "confidence": 0.9839229583740234
        },
        {
          "text": "1.8",
          "bbox": [
            478.0,
            1073.0,
            562.0,
            1124.0
          ],
          "confidence": 0.999962329864502
        },
        {
          "text": "CMO means contract manufacturing organization.",
          "bbox": [
            723.0,
            1073.0,
            1749.0,
            1126.0
          ],
          "confidence": 0.9971001744270325
        },
        {
          "text": "1.9",
          "bbox": [
            478.0,
            1191.0,
            560.0,
            1243.0
          ],
          "confidence": 0.9999006390571594
        },
        {
          "text": "Commercially Reasonable Efforts means, with respect to the efforts to be used by a Party under this",
          "bbox": [
            725.0,
            1195.0,
            3023.0,
            1241.0
          ],
          "confidence": 0.997243344783783
        },
        {
          "text": "Agreement with respect to the Licensed Products, those efforts and resources normally used by a major pharmaceutical or a",
          "bbox": [
            283.0,
            1263.0,
            3025.0,
            1307.0
          ],
          "confidence": 0.9916821718215942
        },
        {
          "text": "sufficiently financed biotechnology company for a product owned by it, or to which it has rights, which is of similar market potential at",
          "bbox": [
            277.0,
            1321.0,
            3029.0,
            1372.0
          ],
          "confidence": 0.9948831796646118
        },
        {
          "text": "comparable stages of development, taking into account the competitiveness of the marketplace, the proprietary position of the product.",
          "bbox": [
            281.0,
            1389.0,
            3023.0,
            1433.0
          ],
          "confidence": 0.9958548545837402
        },
        {
          "text": "the performance of other products that are of similar market potential and the likely timing of other product's entry into the market,",
          "bbox": [
            281.0,
            1453.0,
            3023.0,
            1497.0
          ],
          "confidence": 0.9958077073097229
        },
        {
          "text": "the regulatory structure involved, the profitability of the applicable product, relevant Third Party intellectual property necessary to",
          "bbox": [
            281.0,
            1515.0,
            3025.0,
            1559.0
          ],
          "confidence": 0.9959139227867126
        },
        {
          "text": "manufacture or Commercialize the Licensed Product and other relevant factors commonly considered in similar circumstances,",
          "bbox": [
            275.0,
            1571.0,
            3029.0,
            1625.0
          ],
          "confidence": 0.995061457157135
        },
        {
          "text": "including technical, legal, scientific or medical factors.",
          "bbox": [
            281.0,
            1641.0,
            1372.0,
            1685.0
          ],
          "confidence": 0.9983561038970947
        },
        {
          "text": "1.10",
          "bbox": [
            480.0,
            1754.0,
            589.0,
            1802.0
          ],
          "confidence": 0.9999697208404541
        },
        {
          "text": "Commercialization means the conduct of all activities undertaken before and after Regulatory Approval.",
          "bbox": [
            750.0,
            1754.0,
            3029.0,
            1805.0
          ],
          "confidence": 0.9943490624427795
        },
        {
          "text": "relating to the promotion, marketing, sale and distribution (including importing, exporting, transporting, customs clearance, warehousing,",
          "bbox": [
            275.0,
            1820.0,
            3025.0,
            1873.0
          ],
          "confidence": 0.9991621971130371
        },
        {
          "text": "invoicing, handling and delivering products to customers) of pharmaceutical products, including: (a) sales force efforts, detailing,",
          "bbox": [
            277.0,
            1882.0,
            3023.0,
            1935.0
          ],
          "confidence": 0.989540696144104
        },
        {
          "text": "advertising, medical education, planning, marketing, sales force training and sales and distribution; and (b) scientific and medical",
          "bbox": [
            281.0,
            1950.0,
            3029.0,
            1994.0
          ],
          "confidence": 0.9934641718864441
        },
        {
          "text": "affairs. For clarity, Commercialization does not include any Development activities, whether conducted before or after Regulatory.",
          "bbox": [
            275.0,
            2005.0,
            3025.0,
            2063.0
          ],
          "confidence": 0.991479754447937
        },
        {
          "text": "Approval. \"Commercialize\"' and \"Commercializing\"' have correlative meanings..",
          "bbox": [
            279.0,
            2076.0,
            1956.0,
            2127.0
          ],
          "confidence": 0.9811223745346069
        },
        {
          "text": "1.11",
          "bbox": [
            480.0,
            2189.0,
            582.0,
            2237.0
          ],
          "confidence": 0.9999496936798096
        },
        {
          "text": "Competitive Product means (i) any product which contains Ranibizumab and is either a Reference Product or",
          "bbox": [
            752.0,
            2195.0,
            3027.0,
            2238.0
          ],
          "confidence": 0.9990459084510803
        },
        {
          "text": "a biosimilar to a Reference Product, but excluding in any case the Licensed Products, (ii) [***] (but for clarity [***]) or (iii) [***] (but",
          "bbox": [
            277.0,
            2255.0,
            3029.0,
            2304.0
          ],
          "confidence": 0.988621175289154
        },
        {
          "text": "for clarity [***])",
          "bbox": [
            279.0,
            2319.0,
            625.0,
            2368.0
          ],
          "confidence": 0.9934876561164856
        },
        {
          "text": "1.12",
          "bbox": [
            478.0,
            2430.0,
            587.0,
            2483.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Competitor means any person or entity (other than the Parties and their Affiliates) which has initiated and is",
          "bbox": [
            750.0,
            2438.0,
            3027.0,
            2487.0
          ],
          "confidence": 0.9882062673568726
        },
        {
          "text": "then-active in [***] the marketing, selling or distribution of a Competitive Product, [***] in the Territory, as well as any Affiliate of",
          "bbox": [
            279.0,
            2500.0,
            3032.0,
            2549.0
          ],
          "confidence": 0.9960110783576965
        },
        {
          "text": "any such person or entity..",
          "bbox": [
            283.0,
            2567.0,
            798.0,
            2611.0
          ],
          "confidence": 0.9808448553085327
        },
        {
          "text": "1.13",
          "bbox": [
            477.0,
            2675.0,
            587.0,
            2728.0
          ],
          "confidence": 0.9999721050262451
        },
        {
          "text": "Competitor Change of Control means any of the following events after the Effective Date:.",
          "bbox": [
            752.0,
            2681.0,
            2644.0,
            2732.0
          ],
          "confidence": 0.9916378259658813
        },
        {
          "text": "(a)",
          "bbox": [
            480.0,
            2794.0,
            547.0,
            2847.0
          ],
          "confidence": 0.9996528625488281
        },
        {
          "text": "any Competitor (i) becomes the beneficial owner, directly or indirectly, of shares of capital stock or other.",
          "bbox": [
            868.0,
            2794.0,
            3023.0,
            2842.0
          ],
          "confidence": 0.9901131391525269
        },
        {
          "text": "interests (including partnership interests) of the Licensee then outstanding and normally entitled (without regard to the occurrence of",
          "bbox": [
            279.0,
            2858.0,
            3032.0,
            2905.0
          ],
          "confidence": 0.9926522970199585
        },
        {
          "text": "representing more than fifty percent (50%) of the total voting power of all outstanding classes of Voting Stock of the Licensee or (ii)",
          "bbox": [
            274.0,
            2988.0,
            3023.0,
            3039.0
          ],
          "confidence": 0.9979057908058167
        },
        {
          "text": "of the Licensee's board of directors, supervisory board or similar governing body (Board of Directors); or.",
          "bbox": [
            279.0,
            3119.0,
            2460.0,
            3165.0
          ],
          "confidence": 0.9923440217971802
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4435.0,
            1437.0,
            4477.0
          ],
          "confidence": 0.991787850856781
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Change Of Control_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Bioeq may terminate this Agreement immediately upon written notice to Licensee, if Licensee conducts any clinical development of, markets, sells or distributes any Competitive Product in the Territory, whether directly or indirectly through the intermediary of a Third Party or its Affiliates (Restricted Activities); provided, that in the event that Restricted Activities are being or would be deemed to be conducted by Licensee solely in connection with a Competitor Change of Control, Bioeq may not terminate this Agreement in accordance with this Section 15.2.2 and instead may terminate this Agreement in accordance with Section 15.2.9.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Change Of Control_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Bioeq may terminate this Agreement immediately upon written notice to Licensee, if Licensee conducts any clinical development of, markets, sells or distributes any Competitive Product in the Territory, whether directly or indirectly through the intermediary of a Third Party or its Affiliates (Restricted Activities); provided, that in the event that Restricted Activities are being or would be deemed to be conducted by Licensee solely in connection with a Competitor Change of Control, Bioeq may not terminate this Agreement in accordance with this Section 15.2.2 and instead may terminate this Agreement in accordance with Section 15.2.9.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Change Of Control_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Upon the consummation of such definitive agreement, if Licensee has not then divested all such Competitive Products such that a Competitor Change of Control has occurred, Bioeq may, upon sending written notice to Licensee within sixty (60) days thereafter, terminate this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Change Of Control_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Upon the consummation of such definitive agreement, if Licensee has not then divested all such Competitive Products such that a Competitor Change of Control has occurred, Bioeq may, upon sending written notice to Licensee within sixty (60) days thereafter, terminate this Agreement.",
      "page_number": 3,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9717634320259094
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.9994022250175476
        },
        {
          "text": "1.5",
          "bbox": [
            480.0,
            402.0,
            562.0,
            453.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "Biologics License Application or BLA means a request for permission to introduce, or deliver for introduction,",
          "bbox": [
            727.0,
            409.0,
            3025.0,
            453.0
          ],
          "confidence": 0.9921256899833679
        },
        {
          "text": "a biologic product into interstate commerce (21 CFR 601.2) to the FDA, including any supplements, addendums, or amendments",
          "bbox": [
            281.0,
            473.0,
            3025.0,
            517.0
          ],
          "confidence": 0.9932877421379089
        },
        {
          "text": "thereto. For the avoidance of doubt, the term Biologics License Application or BLA shall include any Abbreviated Biologics License",
          "bbox": [
            281.0,
            535.0,
            3025.0,
            579.0
          ],
          "confidence": 0.9936209917068481
        },
        {
          "text": "Application.",
          "bbox": [
            279.0,
            598.0,
            524.0,
            647.0
          ],
          "confidence": 0.9999745488166809
        },
        {
          "text": "1.6",
          "bbox": [
            480.0,
            711.0,
            562.0,
            762.0
          ],
          "confidence": 0.9999096989631653
        },
        {
          "text": "Biologics License Application Approval means issuance of a Department of Health and Human Services",
          "bbox": [
            723.0,
            713.0,
            3029.0,
            764.0
          ],
          "confidence": 0.9958980083465576
        },
        {
          "text": "U.S. License under 351(k) of the Public Health Services Act controlling the manufacture and sale of biologic products or any",
          "bbox": [
            277.0,
            775.0,
            3025.0,
            830.0
          ],
          "confidence": 0.9973142147064209
        },
        {
          "text": "successor statutory provisions thereof..",
          "bbox": [
            275.0,
            842.0,
            1066.0,
            890.0
          ],
          "confidence": 0.9804762005805969
        },
        {
          "text": "1.7",
          "bbox": [
            480.0,
            958.0,
            562.0,
            1009.0
          ],
          "confidence": 0.9998540878295898
        },
        {
          "text": "BPCIA means the Biologics Price Competition and Innovation Act of 2009, as amended..",
          "bbox": [
            723.0,
            958.0,
            2539.0,
            1009.0
          ],
          "confidence": 0.9839229583740234
        },
        {
          "text": "1.8",
          "bbox": [
            478.0,
            1073.0,
            562.0,
            1124.0
          ],
          "confidence": 0.999962329864502
        },
        {
          "text": "CMO means contract manufacturing organization.",
          "bbox": [
            723.0,
            1073.0,
            1749.0,
            1126.0
          ],
          "confidence": 0.9971001744270325
        },
        {
          "text": "1.9",
          "bbox": [
            478.0,
            1191.0,
            560.0,
            1243.0
          ],
          "confidence": 0.9999006390571594
        },
        {
          "text": "Commercially Reasonable Efforts means, with respect to the efforts to be used by a Party under this",
          "bbox": [
            725.0,
            1195.0,
            3023.0,
            1241.0
          ],
          "confidence": 0.997243344783783
        },
        {
          "text": "Agreement with respect to the Licensed Products, those efforts and resources normally used by a major pharmaceutical or a",
          "bbox": [
            283.0,
            1263.0,
            3025.0,
            1307.0
          ],
          "confidence": 0.9916821718215942
        },
        {
          "text": "sufficiently financed biotechnology company for a product owned by it, or to which it has rights, which is of similar market potential at",
          "bbox": [
            277.0,
            1321.0,
            3029.0,
            1372.0
          ],
          "confidence": 0.9948831796646118
        },
        {
          "text": "comparable stages of development, taking into account the competitiveness of the marketplace, the proprietary position of the product.",
          "bbox": [
            281.0,
            1389.0,
            3023.0,
            1433.0
          ],
          "confidence": 0.9958548545837402
        },
        {
          "text": "the performance of other products that are of similar market potential and the likely timing of other product's entry into the market,",
          "bbox": [
            281.0,
            1453.0,
            3023.0,
            1497.0
          ],
          "confidence": 0.9958077073097229
        },
        {
          "text": "the regulatory structure involved, the profitability of the applicable product, relevant Third Party intellectual property necessary to",
          "bbox": [
            281.0,
            1515.0,
            3025.0,
            1559.0
          ],
          "confidence": 0.9959139227867126
        },
        {
          "text": "manufacture or Commercialize the Licensed Product and other relevant factors commonly considered in similar circumstances,",
          "bbox": [
            275.0,
            1571.0,
            3029.0,
            1625.0
          ],
          "confidence": 0.995061457157135
        },
        {
          "text": "including technical, legal, scientific or medical factors.",
          "bbox": [
            281.0,
            1641.0,
            1372.0,
            1685.0
          ],
          "confidence": 0.9983561038970947
        },
        {
          "text": "1.10",
          "bbox": [
            480.0,
            1754.0,
            589.0,
            1802.0
          ],
          "confidence": 0.9999697208404541
        },
        {
          "text": "Commercialization means the conduct of all activities undertaken before and after Regulatory Approval.",
          "bbox": [
            750.0,
            1754.0,
            3029.0,
            1805.0
          ],
          "confidence": 0.9943490624427795
        },
        {
          "text": "relating to the promotion, marketing, sale and distribution (including importing, exporting, transporting, customs clearance, warehousing,",
          "bbox": [
            275.0,
            1820.0,
            3025.0,
            1873.0
          ],
          "confidence": 0.9991621971130371
        },
        {
          "text": "invoicing, handling and delivering products to customers) of pharmaceutical products, including: (a) sales force efforts, detailing,",
          "bbox": [
            277.0,
            1882.0,
            3023.0,
            1935.0
          ],
          "confidence": 0.989540696144104
        },
        {
          "text": "advertising, medical education, planning, marketing, sales force training and sales and distribution; and (b) scientific and medical",
          "bbox": [
            281.0,
            1950.0,
            3029.0,
            1994.0
          ],
          "confidence": 0.9934641718864441
        },
        {
          "text": "affairs. For clarity, Commercialization does not include any Development activities, whether conducted before or after Regulatory.",
          "bbox": [
            275.0,
            2005.0,
            3025.0,
            2063.0
          ],
          "confidence": 0.991479754447937
        },
        {
          "text": "Approval. \"Commercialize\"' and \"Commercializing\"' have correlative meanings..",
          "bbox": [
            279.0,
            2076.0,
            1956.0,
            2127.0
          ],
          "confidence": 0.9811223745346069
        },
        {
          "text": "1.11",
          "bbox": [
            480.0,
            2189.0,
            582.0,
            2237.0
          ],
          "confidence": 0.9999496936798096
        },
        {
          "text": "Competitive Product means (i) any product which contains Ranibizumab and is either a Reference Product or",
          "bbox": [
            752.0,
            2195.0,
            3027.0,
            2238.0
          ],
          "confidence": 0.9990459084510803
        },
        {
          "text": "a biosimilar to a Reference Product, but excluding in any case the Licensed Products, (ii) [***] (but for clarity [***]) or (iii) [***] (but",
          "bbox": [
            277.0,
            2255.0,
            3029.0,
            2304.0
          ],
          "confidence": 0.988621175289154
        },
        {
          "text": "for clarity [***])",
          "bbox": [
            279.0,
            2319.0,
            625.0,
            2368.0
          ],
          "confidence": 0.9934876561164856
        },
        {
          "text": "1.12",
          "bbox": [
            478.0,
            2430.0,
            587.0,
            2483.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Competitor means any person or entity (other than the Parties and their Affiliates) which has initiated and is",
          "bbox": [
            750.0,
            2438.0,
            3027.0,
            2487.0
          ],
          "confidence": 0.9882062673568726
        },
        {
          "text": "then-active in [***] the marketing, selling or distribution of a Competitive Product, [***] in the Territory, as well as any Affiliate of",
          "bbox": [
            279.0,
            2500.0,
            3032.0,
            2549.0
          ],
          "confidence": 0.9960110783576965
        },
        {
          "text": "any such person or entity..",
          "bbox": [
            283.0,
            2567.0,
            798.0,
            2611.0
          ],
          "confidence": 0.9808448553085327
        },
        {
          "text": "1.13",
          "bbox": [
            477.0,
            2675.0,
            587.0,
            2728.0
          ],
          "confidence": 0.9999721050262451
        },
        {
          "text": "Competitor Change of Control means any of the following events after the Effective Date:.",
          "bbox": [
            752.0,
            2681.0,
            2644.0,
            2732.0
          ],
          "confidence": 0.9916378259658813
        },
        {
          "text": "(a)",
          "bbox": [
            480.0,
            2794.0,
            547.0,
            2847.0
          ],
          "confidence": 0.9996528625488281
        },
        {
          "text": "any Competitor (i) becomes the beneficial owner, directly or indirectly, of shares of capital stock or other.",
          "bbox": [
            868.0,
            2794.0,
            3023.0,
            2842.0
          ],
          "confidence": 0.9901131391525269
        },
        {
          "text": "interests (including partnership interests) of the Licensee then outstanding and normally entitled (without regard to the occurrence of",
          "bbox": [
            279.0,
            2858.0,
            3032.0,
            2905.0
          ],
          "confidence": 0.9926522970199585
        },
        {
          "text": "representing more than fifty percent (50%) of the total voting power of all outstanding classes of Voting Stock of the Licensee or (ii)",
          "bbox": [
            274.0,
            2988.0,
            3023.0,
            3039.0
          ],
          "confidence": 0.9979057908058167
        },
        {
          "text": "of the Licensee's board of directors, supervisory board or similar governing body (Board of Directors); or.",
          "bbox": [
            279.0,
            3119.0,
            2460.0,
            3165.0
          ],
          "confidence": 0.9923440217971802
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4435.0,
            1437.0,
            4477.0
          ],
          "confidence": 0.991787850856781
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Except as otherwise expressly provided under this Agreement, neither Party may assign or otherwise transfer this Agreement or any right or obligation hereunder (whether voluntarily, by operation of law or otherwise), without the prior express written consent of the other Party; except however, that either Party shall be permitted to effect such an assignment or transfer without the consent of the other Party to (a) any of its Affiliates or (b) in connection with a sale of all or substantially all of its assets to which this Agreement relates, whether by merger, acquisition, asset sale, stock purchase, or otherwise, but in any event subject to Bioeq's ability to terminate this Agreement in accordance with Section 15.2.9 (for the avoidance of doubt, such termination right pursuant to Section 15.2.9 shall apply mutatis mutandis in case of assignment of the Agreement to a Competitor in all cases listed under subsection (b) above)",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Anti-Assignment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Except as otherwise expressly provided under this Agreement, neither Party may assign or otherwise transfer this Agreement or any right or obligation hereunder (whether voluntarily, by operation of law or otherwise), without the prior express written consent of the other Party; except however, that either Party shall be permitted to effect such an assignment or transfer without the consent of the other Party to (a) any of its Affiliates or (b) in connection with a sale of all or substantially all of its assets to which this Agreement relates, whether by merger, acquisition, asset sale, stock purchase, or otherwise, but in any event subject to Bioeq's ability to terminate this Agreement in accordance with Section 15.2.9 (for the avoidance of doubt, such termination right pursuant to Section 15.2.9 shall apply mutatis mutandis in case of assignment of the Agreement to a Competitor in all cases listed under subsection (b) above)",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Licensee shall be entitled to freely subcontract or delegate any of its rights or obligations under this Agreement to its Affiliates or to Third Parties, provided that (i) all sales of Licensed Products in the Field in the Territory continue to be made by Licensee or its Affiliates (or their wholesalers or distributors) and (ii) Licensee shall remain liable for the performance of its obligations under this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Anti-Assignment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Licensee shall be entitled to freely subcontract or delegate any of its rights or obligations under this Agreement to its Affiliates or to Third Parties, provided that (i) all sales of Licensed Products in the Field in the Territory continue to be made by Licensee or its Affiliates (or their wholesalers or distributors) and (ii) Licensee shall remain liable for the performance of its obligations under this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Anti-Assignment_4",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Any purported assignment or transfer in violation of this Section 16.4 shall be null and void.",
      "page_number": 4,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9777219891548157
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3025.0,
            384.0
          ],
          "confidence": 0.9990074038505554
        },
        {
          "text": "(b)",
          "bbox": [
            486.0,
            406.0,
            542.0,
            451.0
          ],
          "confidence": 0.9973199963569641
        },
        {
          "text": "the Licensee enters into a merger, consolidation or similar transaction with a Competitor (whether or not.",
          "bbox": [
            870.0,
            402.0,
            3025.0,
            450.0
          ],
          "confidence": 0.9922320246696472
        },
        {
          "text": "such Party is the surviving entity) and as a result of such merger, consolidation or similar transaction (i) the managing directors or the.",
          "bbox": [
            281.0,
            470.0,
            3027.0,
            513.0
          ],
          "confidence": 0.9920163750648499
        },
        {
          "text": "members of the Board of Directors of the Licensee immediately prior to such transaction constitute less than a majority of the",
          "bbox": [
            277.0,
            530.0,
            3025.0,
            576.0
          ],
          "confidence": 0.9923511743545532
        },
        {
          "text": "managing directors or the members of the Board of Directors of the Licensee or such surviving person immediately following such",
          "bbox": [
            277.0,
            594.0,
            3027.0,
            643.0
          ],
          "confidence": 0.9862891435623169
        },
        {
          "text": "transaction or (ii) the persons that beneficially owned, directly or indirectly, the shares of Voting Stock of the Licensee immediately",
          "bbox": [
            277.0,
            656.0,
            3023.0,
            704.0
          ],
          "confidence": 0.9987921714782715
        },
        {
          "text": "prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of the Licensee representing a",
          "bbox": [
            275.0,
            718.0,
            3031.0,
            769.0
          ],
          "confidence": 0.9947993159294128
        },
        {
          "text": "majority of the total voting power of all outstanding classes of Voting Stock of the surviving person in substantially the same",
          "bbox": [
            279.0,
            786.0,
            3027.0,
            830.0
          ],
          "confidence": 0.9937988519668579
        },
        {
          "text": "proportions as their ownership of Voting Stock of the Licensee immediately prior to such transaction.",
          "bbox": [
            277.0,
            844.0,
            2342.0,
            895.0
          ],
          "confidence": 0.9985789060592651
        },
        {
          "text": "1.14",
          "bbox": [
            480.0,
            961.0,
            589.0,
            1009.0
          ],
          "confidence": 0.9999711513519287
        },
        {
          "text": "Confidential Information means, with respect to a Party, all Know-How and all other proprietary information.",
          "bbox": [
            754.0,
            967.0,
            3025.0,
            1011.0
          ],
          "confidence": 0.9920302629470825
        },
        {
          "text": "of such Party, including information on the business, affairs, research and development activities, results of non-clinical and clinical.",
          "bbox": [
            281.0,
            1031.0,
            3027.0,
            1074.0
          ],
          "confidence": 0.989547848701477
        },
        {
          "text": "trials, national and multinational regulatory proceedings and affairs, finances, plans, contractual relationships and operations of such.",
          "bbox": [
            281.0,
            1095.0,
            3025.0,
            1138.0
          ],
          "confidence": 0.9868026971817017
        },
        {
          "text": "Party. Furthermore, the terms and conditions of this Agreement shall be considered Confidential Information of both Parties. For the",
          "bbox": [
            281.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9930081367492676
        },
        {
          "text": "avoidance of doubt, all Know-How and proprietary information relating to the Licensed Products generated by or on behalf of Bioeq.",
          "bbox": [
            277.0,
            1217.0,
            3027.0,
            1265.0
          ],
          "confidence": 0.989470362663269
        },
        {
          "text": "and provided to Licensee hereunder shall be considered Confidential Information of Bioeq.",
          "bbox": [
            279.0,
            1277.0,
            2128.0,
            1330.0
          ],
          "confidence": 0.9949022531509399
        },
        {
          "text": "1.15",
          "bbox": [
            480.0,
            1396.0,
            589.0,
            1444.0
          ],
          "confidence": 0.9999708533287048
        },
        {
          "text": "Control (whether used as a noun or as a verb) or Controlled means, with respect to any Intellectual Property",
          "bbox": [
            752.0,
            1396.0,
            3025.0,
            1451.0
          ],
          "confidence": 0.9984130859375
        },
        {
          "text": "Right, Trademark or Know-How, the possession (whether by ownership or license, other than pursuant to this Agreement) by a Party",
          "bbox": [
            277.0,
            1462.0,
            3023.0,
            1513.0
          ],
          "confidence": 0.9943523406982422
        },
        {
          "text": "of the ability to grant to the other Party access or a license as provided herein under such Intellectual Property Right, Trademark or",
          "bbox": [
            281.0,
            1529.0,
            3027.0,
            1573.0
          ],
          "confidence": 0.9949034452438354
        },
        {
          "text": "Know-How without violating the terms of any agreement or other arrangements with any Third Party.",
          "bbox": [
            279.0,
            1590.0,
            2369.0,
            1637.0
          ],
          "confidence": 0.9864059686660767
        },
        {
          "text": "1.16",
          "bbox": [
            478.0,
            1698.0,
            591.0,
            1752.0
          ],
          "confidence": 0.9999558925628662
        },
        {
          "text": "Damages shall have the meaning ascribed to it in Section 9.4.3..",
          "bbox": [
            750.0,
            1701.0,
            2059.0,
            1752.0
          ],
          "confidence": 0.9965372681617737
        },
        {
          "text": "1.17",
          "bbox": [
            478.0,
            1818.0,
            591.0,
            1871.0
          ],
          "confidence": 0.9999223351478577
        },
        {
          "text": "Defend or Defense shall have the meaning ascribed to it in Section 9.4.2..",
          "bbox": [
            750.0,
            1820.0,
            2258.0,
            1871.0
          ],
          "confidence": 0.9893102049827576
        },
        {
          "text": "1.18",
          "bbox": [
            478.0,
            1937.0,
            591.0,
            1990.0
          ],
          "confidence": 0.9999673366546631
        },
        {
          "text": "Development means all non-clinical and clinical research and drug development activities as well as.",
          "bbox": [
            754.0,
            1944.0,
            3025.0,
            1988.0
          ],
          "confidence": 0.9888492822647095
        },
        {
          "text": "Manufacturing process development, upscaling of the Manufacturing process and chemistry, manufacturing and control development",
          "bbox": [
            279.0,
            2006.0,
            3027.0,
            2052.0
          ],
          "confidence": 0.9937490820884705
        },
        {
          "text": "work conducted in respect of any pharmaceutical product, including those necessary to obtain Regulatory Approval for such",
          "bbox": [
            281.0,
            2072.0,
            3027.0,
            2116.0
          ],
          "confidence": 0.9899325370788574
        },
        {
          "text": "pharmaceutical product. When used as a verb, Develop means to engage in Development.",
          "bbox": [
            279.0,
            2134.0,
            2148.0,
            2186.0
          ],
          "confidence": 0.9984303712844849
        },
        {
          "text": "1.19",
          "bbox": [
            478.0,
            2246.0,
            589.0,
            2299.0
          ],
          "confidence": 0.9999583959579468
        },
        {
          "text": "Disclosing Party shall have the meaning ascribed to it in Section 11.1.",
          "bbox": [
            752.0,
            2251.0,
            2195.0,
            2301.0
          ],
          "confidence": 0.9872499704360962
        },
        {
          "text": "1.20",
          "bbox": [
            478.0,
            2366.0,
            585.0,
            2414.0
          ],
          "confidence": 0.9999449253082275
        },
        {
          "text": "Effective Date shall have the meaning ascribed to it in the introductory paragraph above",
          "bbox": [
            752.0,
            2368.0,
            2572.0,
            2418.0
          ],
          "confidence": 0.9994855523109436
        },
        {
          "text": "1.21",
          "bbox": [
            478.0,
            2485.0,
            587.0,
            2538.0
          ],
          "confidence": 0.9999347925186157
        },
        {
          "text": "Existing Reference Product shall have the meaning ascribed to it in Section 1.61..",
          "bbox": [
            750.0,
            2487.0,
            2443.0,
            2538.0
          ],
          "confidence": 0.9832090735435486
        },
        {
          "text": "1.22",
          "bbox": [
            478.0,
            2600.0,
            589.0,
            2653.0
          ],
          "confidence": 0.9999254941940308
        },
        {
          "text": "FDA means the United States Food and Drug Administration, and any successor agency thereto",
          "bbox": [
            750.0,
            2602.0,
            2737.0,
            2655.0
          ],
          "confidence": 0.991290807723999
        },
        {
          "text": "1.23",
          "bbox": [
            480.0,
            2721.0,
            587.0,
            2768.0
          ],
          "confidence": 0.9999662041664124
        },
        {
          "text": "Field means any human use of the Licensed Product in the field of ophthalmology and for any other approved",
          "bbox": [
            749.0,
            2719.0,
            3029.0,
            2778.0
          ],
          "confidence": 0.9872778654098511
        },
        {
          "text": "labelled indication of such Licensed Products..",
          "bbox": [
            281.0,
            2789.0,
            1209.0,
            2831.0
          ],
          "confidence": 0.9907771944999695
        },
        {
          "text": "1.24",
          "bbox": [
            478.0,
            2900.0,
            589.0,
            2955.0
          ],
          "confidence": 0.9999393224716187
        },
        {
          "text": "First Commercial Sale means, with respect to any Licensed Product in the Territory, the first sale by",
          "bbox": [
            750.0,
            2904.0,
            3025.0,
            2957.0
          ],
          "confidence": 0.9871525764465332
        },
        {
          "text": "Licensee or its Affiliates of such Licensed Product to a Third Party for use in the Field in the Territory, after such Licensed Product.",
          "bbox": [
            277.0,
            2969.0,
            3027.0,
            3015.0
          ],
          "confidence": 0.9941776394844055
        },
        {
          "text": "has been granted Regulatory Approval for use in the Field in the Territory..",
          "bbox": [
            277.0,
            3033.0,
            1793.0,
            3083.0
          ],
          "confidence": 0.9928413033485413
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9924864768981934
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "In addition, Licensee shall pay to Bioeq the following royalties on Licensee's and its Affiliates' Gross Margins (calculated in accordance with Section 7.3.3) generated through the sale of Licensed Products in the Field in the Territory:\n\n(a) Prior to [***], Licensee shall pay to Bioeq royalties in the amount of [***] percent ([***]%) on Licensee's and its Affiliates' Gross Margins (calculated in accordance with Section 7.3.3) generated through the sale of Licensed Products in the Field in the Territory, payable on a Licensed Product-by-Licensed Product basis, and subject to Section 7.3.1(c) hereunder.\n\n(b) Starting [***], Licensee shall pay to Bioeq royalties in the amount of [***] percent ([***]%) on the Licensee's and its Affiliates' Gross Margins generated through the sale of Licensed Products in the Field in the Territory, payable on a Licensed ProductâbyâLicensed Product basis, and subject to Section 7.3.1(c) hereunder.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Revenue/Profit Sharing_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "In addition, Licensee shall pay to Bioeq the following royalties on Licensee's and its Affiliates' Gross Margins (calculated in accordance with Section 7.3.3) generated through the sale of Licensed Products in the Field in the Territory:\n\n(a) Prior to [***], Licensee shall pay to Bioeq royalties in the amount of [***] percent ([***]%) on Licensee's and its Affiliates' Gross Margins (calculated in accordance with Section 7.3.3) generated through the sale of Licensed Products in the Field in the Territory, payable on a Licensed Product-by-Licensed Product basis, and subject to Section 7.3.1(c) hereunder.\n\n(b) Starting [***], Licensee shall pay to Bioeq royalties in the amount of [***] percent ([***]%) on the Licensee's and its Affiliates' Gross Margins generated through the sale of Licensed Products in the Field in the Territory, payable on a Licensed ProductâbyâLicensed Product basis, and subject to Section 7.3.1(c) hereunder.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Revenue/Profit Sharing_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "The license granted by Licensee pursuant to Section 9.2.2 shall be extended to also include the Development, Manufacture, sale, import or other Commercialization of Licensed Products in the Field in the Territory, and, unless this Agreement is terminated by Bioeq pursuant to pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5 (in [***]), such license shall thereafter be royalty-bearing on Bioeq on Net Sales (applied mutatis mutandis as if Bioeq were Licensee, and additionally applying to sales by sublicensees of Bioeq) by Bioeq, its Affiliates, and its sublicensees of Licensed Products in the Field in the Territory which have [***] Licensee Improvement, at [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.29",
          "bbox": [
            2775.0,
            283.0,
            3027.0,
            325.0
          ],
          "confidence": 0.9998047947883606
        },
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            344.0,
            3030.0,
            382.0
          ],
          "confidence": 0.999879777431488
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            404.0,
            3027.0,
            440.0
          ],
          "confidence": 0.999829888343811
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not",
          "bbox": [
            321.0,
            460.0,
            2991.0,
            503.0
          ],
          "confidence": 0.9897100329399109
        },
        {
          "text": "material and would likely cause competitive harm to the registrant if publicly disclosed.",
          "bbox": [
            825.0,
            515.0,
            2478.0,
            559.0
          ],
          "confidence": 0.9881774187088013
        },
        {
          "text": "NOV 02, 2019",
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ],
          "confidence": 0.9989316463470459
        },
        {
          "text": "BIOEQ IP AG",
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ],
          "confidence": 0.998244047164917
        },
        {
          "text": "AND",
          "bbox": [
            1595.0,
            1986.0,
            1715.0,
            2034.0
          ],
          "confidence": 0.9988322257995605
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ],
          "confidence": 0.9984176158905029
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ],
          "confidence": 0.9851366877555847
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9914476871490479
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "The license granted by Licensee pursuant to Section 9.2.2 shall be extended to also include the Development, Manufacture, sale, import or other Commercialization of Licensed Products in the Field in the Territory, and, unless this Agreement is terminated by Bioeq pursuant to pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5 (in [***]), such license shall thereafter be royalty-bearing on Bioeq on Net Sales (applied mutatis mutandis as if Bioeq were Licensee, and additionally applying to sales by sublicensees of Bioeq) by Bioeq, its Affiliates, and its sublicensees of Licensed Products in the Field in the Territory which have [***] Licensee Improvement, at [***].",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Minimum Commitment_2",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "In particular, Licensee commits to:",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Minimum Commitment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "(c) dedicate the minimum pre-launch and post-launch resources specified in Section B of Schedule 6.2(c) to its Commercialization of the Licensed Products in the Territory in accordance with the Commercialization Plan during each year ([***]) after the First Commercial Sale of any Licensed Product in the Field in the Territory until [***] (Commercialization Commitment Period); provided that if Licensee [***], then the commercialization commitments as set forth in Section B of Schedule 6.2(c) shall continue to apply except that the [***]. For clarity, after the expiration of the Commercialization Commitment Period, Licensee shall have no further obligation under this Section 6.2(c).",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Minimum Commitment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "(c) dedicate the minimum pre-launch and post-launch resources specified in Section B of Schedule 6.2(c) to its Commercialization of the Licensed Products in the Territory in accordance with the Commercialization Plan during each year ([***]) after the First Commercial Sale of any Licensed Product in the Field in the Territory until [***] (Commercialization Commitment Period); provided that if Licensee [***], then the commercialization commitments as set forth in Section B of Schedule 6.2(c) shall continue to apply except that the [***]. For clarity, after the expiration of the Commercialization Commitment Period, Licensee shall have no further obligation under this Section 6.2(c).",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Minimum Commitment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "Subject to the second sentence of this Section 15.2.2, Bioeq may notify Licensee of its intent to terminate this Agreement anytime within thirty ([***]) days following the end of any [***] ([***]) month time period starting [***] ([***]) months after the First Commercial Sale of the first [***] Product in the Field in the Territory upon written notice to Licensee, if Licensee, with respect to its sales of Licensed Products in the Field in the Territory, has not achieved an average market share of at least [***] percent ([***]%) of the [***] (such market excluding for clarity in all cases [***]), calculated based on [***] in the Field in the Territory in the [***] ([***]) months prior to the end of such [***] ([***]) month time period (i.e., for example, in months [***] of the [***] after the First Commercial Sale of such [***] Product) (Minimum Market Share Requirement); upon Licensee's receipt of such notice from Bioeq, if Licensee does not achieve the Minimum Market Share Requirement, applied mutatis mutandis, during the subsequent [***] ([***]) months period following its receipt of such notice from Bioeq (Licensee Cure Period), Bioeq may terminate this Agreement upon written notice to Licensee; provided further, that the termination right described in this Section 15.2.2 shall apply only if [***], and provided further that such failure of Licensee to achieve the Minimum Market Share Requirement (i) is not due to any [***] (including [***]); (ii) not due to any [***] Bioeq's right to notify Licensee of its intent to terminate this Agreement in accordance with the first sentence of this Section 15.2.2 shall apply only until [***] ([***]) days after the [***] ([***]) anniversary of the First Commercial Sale of the first [***] Product in the Field in the Territory, after which Bioeq shall have no further rights under this Section 15.2.2.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Minimum Commitment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "Subject to the second sentence of this Section 15.2.2, Bioeq may notify Licensee of its intent to terminate this Agreement anytime within thirty ([***]) days following the end of any [***] ([***]) month time period starting [***] ([***]) months after the First Commercial Sale of the first [***] Product in the Field in the Territory upon written notice to Licensee, if Licensee, with respect to its sales of Licensed Products in the Field in the Territory, has not achieved an average market share of at least [***] percent ([***]%) of the [***] (such market excluding for clarity in all cases [***]), calculated based on [***] in the Field in the Territory in the [***] ([***]) months prior to the end of such [***] ([***]) month time period (i.e., for example, in months [***] of the [***] after the First Commercial Sale of such [***] Product) (Minimum Market Share Requirement); upon Licensee's receipt of such notice from Bioeq, if Licensee does not achieve the Minimum Market Share Requirement, applied mutatis mutandis, during the subsequent [***] ([***]) months period following its receipt of such notice from Bioeq (Licensee Cure Period), Bioeq may terminate this Agreement upon written notice to Licensee; provided further, that the termination right described in this Section 15.2.2 shall apply only if [***], and provided further that such failure of Licensee to achieve the Minimum Market Share Requirement (i) is not due to any [***] (including [***]); (ii) not due to any [***] Bioeq's right to notify Licensee of its intent to terminate this Agreement in accordance with the first sentence of this Section 15.2.2 shall apply only until [***] ([***]) days after the [***] ([***]) anniversary of the First Commercial Sale of the first [***] Product in the Field in the Territory, after which Bioeq shall have no further rights under this Section 15.2.2.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Licensee shall, within [***] ([***]) days of the effective date of termination of the Agreement at the latest (and at no cost to Bioeq if this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5, or at Bioeq's cost and expense if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8, as applicable) transfer and assign to Bioeq or its designee all of Licensee's right, title and interest in and to any and all Biologics License Applications and Biologics License Application Approvals controlled by Licensee for the Licensed Products in the Field in the Territory as of the effective date of such termination, including any and all documentation pertaining to such filings and Biologics License Application Approvals (provided that the physical or electronic transfer of files and documentation in connection with such transfer and assignment of rights may occur after such [***] ([***]) day period without being deemed a breach of this Section 15.3.2 by Licensee).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.29",
          "bbox": [
            2775.0,
            283.0,
            3027.0,
            325.0
          ],
          "confidence": 0.9998047947883606
        },
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            344.0,
            3030.0,
            382.0
          ],
          "confidence": 0.999879777431488
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            404.0,
            3027.0,
            440.0
          ],
          "confidence": 0.999829888343811
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not",
          "bbox": [
            321.0,
            460.0,
            2991.0,
            503.0
          ],
          "confidence": 0.9897100329399109
        },
        {
          "text": "material and would likely cause competitive harm to the registrant if publicly disclosed.",
          "bbox": [
            825.0,
            515.0,
            2478.0,
            559.0
          ],
          "confidence": 0.9881774187088013
        },
        {
          "text": "NOV 02, 2019",
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ],
          "confidence": 0.9989316463470459
        },
        {
          "text": "BIOEQ IP AG",
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ],
          "confidence": 0.998244047164917
        },
        {
          "text": "AND",
          "bbox": [
            1595.0,
            1986.0,
            1715.0,
            2034.0
          ],
          "confidence": 0.9988322257995605
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ],
          "confidence": 0.9984176158905029
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ],
          "confidence": 0.9851366877555847
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9914476871490479
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Licensee shall, within [***] ([***]) days of the effective date of termination of the Agreement at the latest (and at no cost to Bioeq if this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5, or at Bioeq's cost and expense if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8, as applicable) transfer and assign to Bioeq or its designee all of Licensee's right, title and interest in and to any and all Biologics License Applications and Biologics License Application Approvals controlled by Licensee for the Licensed Products in the Field in the Territory as of the effective date of such termination, including any and all documentation pertaining to such filings and Biologics License Application Approvals (provided that the physical or electronic transfer of files and documentation in connection with such transfer and assignment of rights may occur after such [***] ([***]) day period without being deemed a breach of this Section 15.3.2 by Licensee).",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Prior to the First Commercial Sale of any Licensed Product in the Territory, Bioeq shall transfer or cause to be transferred the applicable Regulatory Approvals and Biologics License Applications for such Licensed Product to Licensee, including by preparing and submitting a transfer letter notifying the FDA of the transfer of the applicable Regulatory Approvals and Biologics License Applications for such Licensed Product to Licensee.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Ip Ownership Assignment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Prior to the First Commercial Sale of any Licensed Product in the Territory, Bioeq shall transfer or cause to be transferred the applicable Regulatory Approvals and Biologics License Applications for such Licensed Product to Licensee, including by preparing and submitting a transfer letter notifying the FDA of the transfer of the applicable Regulatory Approvals and Biologics License Applications for such Licensed Product to Licensee.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Notwithstanding any other rights Bioeq may have under this Agreement or Applicable Law; if Licensee does not transfer and assign to Bioeq or its designee its rights in any Biologics License Applications and Biologics License Application Approvals controlled by Licensee for the Licensed Products in the Field in the Territory within the above [***] ([***]) day time period (provided that the physical or electronic transfer of files and documentation in connection with such transfer and assignment",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Ip Ownership Assignment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Notwithstanding any other rights Bioeq may have under this Agreement or Applicable Law; if Licensee does not transfer and assign to Bioeq or its designee its rights in any Biologics License Applications and Biologics License Application Approvals controlled by Licensee for the Licensed Products in the Field in the Territory within the above [***] ([***]) day time period (provided that the physical or electronic transfer of files and documentation in connection with such transfer and assignment",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "In addition, upon Bioeq's request, Licensee shall notify the competent Regulatory Authority of such transfer, supply Bioeq with all documents already prepared by Licensee or its Affiliates for the filing of applications in relation to the Licensed Products with any Regulatory Authority and/or apply for the closing of any such application.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Ip Ownership Assignment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "In addition, upon Bioeq's request, Licensee shall notify the competent Regulatory Authority of such transfer, supply Bioeq with all documents already prepared by Licensee or its Affiliates for the filing of applications in relation to the Licensed Products with any Regulatory Authority and/or apply for the closing of any such application.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Following such transfer, Licensee shall have the sole right and shall use Commercially Reasonable Efforts to maintain such Regulatory Approvals for the Licensed Product in the Field in the Territory at Licensee's expense (subject to the remainder of this Section 4.4), and shall have the sole right to communicate and correspond with Regulatory Authorities in the Territory in connection therewith, in each case, in consultation with Bioeq.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Ip Ownership Assignment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Following such transfer, Licensee shall have the sole right and shall use Commercially Reasonable Efforts to maintain such Regulatory Approvals for the Licensed Product in the Field in the Territory at Licensee's expense (subject to the remainder of this Section 4.4), and shall have the sole right to communicate and correspond with Regulatory Authorities in the Territory in connection therewith, in each case, in consultation with Bioeq.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Ip Ownership Assignment_3",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "of rights may occur after such [***] ([***]) day period without being deemed a breach of this Section 15.3.2 by Licensee), [***].",
      "page_number": 3,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9717634320259094
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.9994022250175476
        },
        {
          "text": "1.5",
          "bbox": [
            480.0,
            402.0,
            562.0,
            453.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "Biologics License Application or BLA means a request for permission to introduce, or deliver for introduction,",
          "bbox": [
            727.0,
            409.0,
            3025.0,
            453.0
          ],
          "confidence": 0.9921256899833679
        },
        {
          "text": "a biologic product into interstate commerce (21 CFR 601.2) to the FDA, including any supplements, addendums, or amendments",
          "bbox": [
            281.0,
            473.0,
            3025.0,
            517.0
          ],
          "confidence": 0.9932877421379089
        },
        {
          "text": "thereto. For the avoidance of doubt, the term Biologics License Application or BLA shall include any Abbreviated Biologics License",
          "bbox": [
            281.0,
            535.0,
            3025.0,
            579.0
          ],
          "confidence": 0.9936209917068481
        },
        {
          "text": "Application.",
          "bbox": [
            279.0,
            598.0,
            524.0,
            647.0
          ],
          "confidence": 0.9999745488166809
        },
        {
          "text": "1.6",
          "bbox": [
            480.0,
            711.0,
            562.0,
            762.0
          ],
          "confidence": 0.9999096989631653
        },
        {
          "text": "Biologics License Application Approval means issuance of a Department of Health and Human Services",
          "bbox": [
            723.0,
            713.0,
            3029.0,
            764.0
          ],
          "confidence": 0.9958980083465576
        },
        {
          "text": "U.S. License under 351(k) of the Public Health Services Act controlling the manufacture and sale of biologic products or any",
          "bbox": [
            277.0,
            775.0,
            3025.0,
            830.0
          ],
          "confidence": 0.9973142147064209
        },
        {
          "text": "successor statutory provisions thereof..",
          "bbox": [
            275.0,
            842.0,
            1066.0,
            890.0
          ],
          "confidence": 0.9804762005805969
        },
        {
          "text": "1.7",
          "bbox": [
            480.0,
            958.0,
            562.0,
            1009.0
          ],
          "confidence": 0.9998540878295898
        },
        {
          "text": "BPCIA means the Biologics Price Competition and Innovation Act of 2009, as amended..",
          "bbox": [
            723.0,
            958.0,
            2539.0,
            1009.0
          ],
          "confidence": 0.9839229583740234
        },
        {
          "text": "1.8",
          "bbox": [
            478.0,
            1073.0,
            562.0,
            1124.0
          ],
          "confidence": 0.999962329864502
        },
        {
          "text": "CMO means contract manufacturing organization.",
          "bbox": [
            723.0,
            1073.0,
            1749.0,
            1126.0
          ],
          "confidence": 0.9971001744270325
        },
        {
          "text": "1.9",
          "bbox": [
            478.0,
            1191.0,
            560.0,
            1243.0
          ],
          "confidence": 0.9999006390571594
        },
        {
          "text": "Commercially Reasonable Efforts means, with respect to the efforts to be used by a Party under this",
          "bbox": [
            725.0,
            1195.0,
            3023.0,
            1241.0
          ],
          "confidence": 0.997243344783783
        },
        {
          "text": "Agreement with respect to the Licensed Products, those efforts and resources normally used by a major pharmaceutical or a",
          "bbox": [
            283.0,
            1263.0,
            3025.0,
            1307.0
          ],
          "confidence": 0.9916821718215942
        },
        {
          "text": "sufficiently financed biotechnology company for a product owned by it, or to which it has rights, which is of similar market potential at",
          "bbox": [
            277.0,
            1321.0,
            3029.0,
            1372.0
          ],
          "confidence": 0.9948831796646118
        },
        {
          "text": "comparable stages of development, taking into account the competitiveness of the marketplace, the proprietary position of the product.",
          "bbox": [
            281.0,
            1389.0,
            3023.0,
            1433.0
          ],
          "confidence": 0.9958548545837402
        },
        {
          "text": "the performance of other products that are of similar market potential and the likely timing of other product's entry into the market,",
          "bbox": [
            281.0,
            1453.0,
            3023.0,
            1497.0
          ],
          "confidence": 0.9958077073097229
        },
        {
          "text": "the regulatory structure involved, the profitability of the applicable product, relevant Third Party intellectual property necessary to",
          "bbox": [
            281.0,
            1515.0,
            3025.0,
            1559.0
          ],
          "confidence": 0.9959139227867126
        },
        {
          "text": "manufacture or Commercialize the Licensed Product and other relevant factors commonly considered in similar circumstances,",
          "bbox": [
            275.0,
            1571.0,
            3029.0,
            1625.0
          ],
          "confidence": 0.995061457157135
        },
        {
          "text": "including technical, legal, scientific or medical factors.",
          "bbox": [
            281.0,
            1641.0,
            1372.0,
            1685.0
          ],
          "confidence": 0.9983561038970947
        },
        {
          "text": "1.10",
          "bbox": [
            480.0,
            1754.0,
            589.0,
            1802.0
          ],
          "confidence": 0.9999697208404541
        },
        {
          "text": "Commercialization means the conduct of all activities undertaken before and after Regulatory Approval.",
          "bbox": [
            750.0,
            1754.0,
            3029.0,
            1805.0
          ],
          "confidence": 0.9943490624427795
        },
        {
          "text": "relating to the promotion, marketing, sale and distribution (including importing, exporting, transporting, customs clearance, warehousing,",
          "bbox": [
            275.0,
            1820.0,
            3025.0,
            1873.0
          ],
          "confidence": 0.9991621971130371
        },
        {
          "text": "invoicing, handling and delivering products to customers) of pharmaceutical products, including: (a) sales force efforts, detailing,",
          "bbox": [
            277.0,
            1882.0,
            3023.0,
            1935.0
          ],
          "confidence": 0.989540696144104
        },
        {
          "text": "advertising, medical education, planning, marketing, sales force training and sales and distribution; and (b) scientific and medical",
          "bbox": [
            281.0,
            1950.0,
            3029.0,
            1994.0
          ],
          "confidence": 0.9934641718864441
        },
        {
          "text": "affairs. For clarity, Commercialization does not include any Development activities, whether conducted before or after Regulatory.",
          "bbox": [
            275.0,
            2005.0,
            3025.0,
            2063.0
          ],
          "confidence": 0.991479754447937
        },
        {
          "text": "Approval. \"Commercialize\"' and \"Commercializing\"' have correlative meanings..",
          "bbox": [
            279.0,
            2076.0,
            1956.0,
            2127.0
          ],
          "confidence": 0.9811223745346069
        },
        {
          "text": "1.11",
          "bbox": [
            480.0,
            2189.0,
            582.0,
            2237.0
          ],
          "confidence": 0.9999496936798096
        },
        {
          "text": "Competitive Product means (i) any product which contains Ranibizumab and is either a Reference Product or",
          "bbox": [
            752.0,
            2195.0,
            3027.0,
            2238.0
          ],
          "confidence": 0.9990459084510803
        },
        {
          "text": "a biosimilar to a Reference Product, but excluding in any case the Licensed Products, (ii) [***] (but for clarity [***]) or (iii) [***] (but",
          "bbox": [
            277.0,
            2255.0,
            3029.0,
            2304.0
          ],
          "confidence": 0.988621175289154
        },
        {
          "text": "for clarity [***])",
          "bbox": [
            279.0,
            2319.0,
            625.0,
            2368.0
          ],
          "confidence": 0.9934876561164856
        },
        {
          "text": "1.12",
          "bbox": [
            478.0,
            2430.0,
            587.0,
            2483.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Competitor means any person or entity (other than the Parties and their Affiliates) which has initiated and is",
          "bbox": [
            750.0,
            2438.0,
            3027.0,
            2487.0
          ],
          "confidence": 0.9882062673568726
        },
        {
          "text": "then-active in [***] the marketing, selling or distribution of a Competitive Product, [***] in the Territory, as well as any Affiliate of",
          "bbox": [
            279.0,
            2500.0,
            3032.0,
            2549.0
          ],
          "confidence": 0.9960110783576965
        },
        {
          "text": "any such person or entity..",
          "bbox": [
            283.0,
            2567.0,
            798.0,
            2611.0
          ],
          "confidence": 0.9808448553085327
        },
        {
          "text": "1.13",
          "bbox": [
            477.0,
            2675.0,
            587.0,
            2728.0
          ],
          "confidence": 0.9999721050262451
        },
        {
          "text": "Competitor Change of Control means any of the following events after the Effective Date:.",
          "bbox": [
            752.0,
            2681.0,
            2644.0,
            2732.0
          ],
          "confidence": 0.9916378259658813
        },
        {
          "text": "(a)",
          "bbox": [
            480.0,
            2794.0,
            547.0,
            2847.0
          ],
          "confidence": 0.9996528625488281
        },
        {
          "text": "any Competitor (i) becomes the beneficial owner, directly or indirectly, of shares of capital stock or other.",
          "bbox": [
            868.0,
            2794.0,
            3023.0,
            2842.0
          ],
          "confidence": 0.9901131391525269
        },
        {
          "text": "interests (including partnership interests) of the Licensee then outstanding and normally entitled (without regard to the occurrence of",
          "bbox": [
            279.0,
            2858.0,
            3032.0,
            2905.0
          ],
          "confidence": 0.9926522970199585
        },
        {
          "text": "representing more than fifty percent (50%) of the total voting power of all outstanding classes of Voting Stock of the Licensee or (ii)",
          "bbox": [
            274.0,
            2988.0,
            3023.0,
            3039.0
          ],
          "confidence": 0.9979057908058167
        },
        {
          "text": "of the Licensee's board of directors, supervisory board or similar governing body (Board of Directors); or.",
          "bbox": [
            279.0,
            3119.0,
            2460.0,
            3165.0
          ],
          "confidence": 0.9923440217971802
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4435.0,
            1437.0,
            4477.0
          ],
          "confidence": 0.991787850856781
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Joint Ip Ownership_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "For those countries where a specific license is required for a joint owner of a Joint Invention or Joint Improvement to practice such Joint Invention or Joint Improvement, in such country, each Party hereby grants to the other Party a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, under such Party's right, title and interest in and to such Joint Invention or Joint Improvement to freely exploit such Joint Invention or Joint Improvement in such country, subject to the terms and conditions of this Agreement and the licenses granted hereunder.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Joint Ip Ownership_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "For those countries where a specific license is required for a joint owner of a Joint Invention or Joint Improvement to practice such Joint Invention or Joint Improvement, in such country, each Party hereby grants to the other Party a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, under such Party's right, title and interest in and to such Joint Invention or Joint Improvement to freely exploit such Joint Invention or Joint Improvement in such country, subject to the terms and conditions of this Agreement and the licenses granted hereunder.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Joint Ip Ownership_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "As between the Parties, the Parties shall jointly own all Inventions (including Improvements) developed, conceived or reduced to practice jointly by or on behalf of both Bioeq and Licensee (such Inventions, Joint Inventions, and such Improvements, Joint Improvements), and all Intellectual Property Rights and Know-How therein.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Joint Ip Ownership_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "As between the Parties, the Parties shall jointly own all Inventions (including Improvements) developed, conceived or reduced to practice jointly by or on behalf of both Bioeq and Licensee (such Inventions, Joint Inventions, and such Improvements, Joint Improvements), and all Intellectual Property Rights and Know-How therein.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Joint Ip Ownership_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "Each Party hereby assigns to the other Party a joint equal and undivided interest in and to all Joint Inventions (including Joint Improvements) to effect such joint ownership of such Joint Inventions (including Joint Improvements).",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Joint Ip Ownership_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "Each Party hereby assigns to the other Party a joint equal and undivided interest in and to all Joint Inventions (including Joint Improvements) to effect such joint ownership of such Joint Inventions (including Joint Improvements).",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the provisions of this Agreement, Bioeq hereby grants to Licensee an exclusive (even as to Bioeq), milestone- and royalty-bearing, non-transferable license (including the right to grant sublicenses only to the extent permitted by Section 2.1.2) under the Licensed Technology (including the Licensed Patents) to use, sell, have sold, import, have imported or otherwise Commercialize the Licensed Products in the Field in the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__License Grant_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the provisions of this Agreement, Bioeq hereby grants to Licensee an exclusive (even as to Bioeq), milestone- and royalty-bearing, non-transferable license (including the right to grant sublicenses only to the extent permitted by Section 2.1.2) under the Licensed Technology (including the Licensed Patents) to use, sell, have sold, import, have imported or otherwise Commercialize the Licensed Products in the Field in the Territory.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Solely in the event that this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9 or by Licensee pursuant to Section 15.2.5 , Licensee shall grant, and hereby grants to Bioeq an exclusive, royalty-free, fully paid, sublicenseable, license to use the Licensee-Controlled Trademarks which were actually used by Licensee to Commercialize the Licensed Products in the Territory in connection with Bioeq's Commercialization of the Licensed Products in the Territory. I",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.29",
          "bbox": [
            2775.0,
            283.0,
            3027.0,
            325.0
          ],
          "confidence": 0.9998047947883606
        },
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            344.0,
            3030.0,
            382.0
          ],
          "confidence": 0.999879777431488
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            404.0,
            3027.0,
            440.0
          ],
          "confidence": 0.999829888343811
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not",
          "bbox": [
            321.0,
            460.0,
            2991.0,
            503.0
          ],
          "confidence": 0.9897100329399109
        },
        {
          "text": "material and would likely cause competitive harm to the registrant if publicly disclosed.",
          "bbox": [
            825.0,
            515.0,
            2478.0,
            559.0
          ],
          "confidence": 0.9881774187088013
        },
        {
          "text": "NOV 02, 2019",
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ],
          "confidence": 0.9989316463470459
        },
        {
          "text": "BIOEQ IP AG",
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ],
          "confidence": 0.998244047164917
        },
        {
          "text": "AND",
          "bbox": [
            1595.0,
            1986.0,
            1715.0,
            2034.0
          ],
          "confidence": 0.9988322257995605
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ],
          "confidence": 0.9984176158905029
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ],
          "confidence": 0.9851366877555847
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9914476871490479
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Solely in the event that this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9 or by Licensee pursuant to Section 15.2.5 , Licensee shall grant, and hereby grants to Bioeq an exclusive, royalty-free, fully paid, sublicenseable, license to use the Licensee-Controlled Trademarks which were actually used by Licensee to Commercialize the Licensed Products in the Territory in connection with Bioeq's Commercialization of the Licensed Products in the Territory. I",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "For those countries where a specific license is required for a joint owner of a Joint Invention or Joint Improvement to practice such Joint Invention or Joint Improvement, in such country, each Party hereby grants to the other Party a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, under such Party's right, title and interest in and to such Joint Invention or Joint Improvement to freely exploit such Joint Invention or Joint Improvement in such country, subject to the terms and conditions of this Agreement and the licenses granted hereunder.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__License Grant_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "For those countries where a specific license is required for a joint owner of a Joint Invention or Joint Improvement to practice such Joint Invention or Joint Improvement, in such country, each Party hereby grants to the other Party a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, under such Party's right, title and interest in and to such Joint Invention or Joint Improvement to freely exploit such Joint Invention or Joint Improvement in such country, subject to the terms and conditions of this Agreement and the licenses granted hereunder.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "or expiration of this Agreement) a non-exclusive, fully-paid, irrevocable license (including the right to grant sublicenses) under all Intellectual Property Rights and Know-How Controlled by Licensee and embodied within, or claiming or covering the Licensee Improvements, to Develop, Manufacture, sell, import, or otherwise Commercialize Licensed Products outside of the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__License Grant_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "or expiration of this Agreement) a non-exclusive, fully-paid, irrevocable license (including the right to grant sublicenses) under all Intellectual Property Rights and Know-How Controlled by Licensee and embodied within, or claiming or covering the Licensee Improvements, to Develop, Manufacture, sell, import, or otherwise Commercialize Licensed Products outside of the Territory.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__License Grant_2",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Licensee hereby grants to Bioeq during the term of this Agreement (and, subject to Section 15.3.4, after termination",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Non-Transferable License_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "Subject to the provisions of this Agreement, Bioeq hereby grants to Licensee an exclusive (even as to Bioeq), milestone- and royalty-bearing, non-transferable license (including the right to grant sublicenses only to the extent permitted by Section 2.1.2) under the Licensed Technology (including the Licensed Patents) to use, sell, have sold, import, have imported or otherwise Commercialize the Licensed Products in the Field in the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Non-Transferable License_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "Subject to the provisions of this Agreement, Bioeq hereby grants to Licensee an exclusive (even as to Bioeq), milestone- and royalty-bearing, non-transferable license (including the right to grant sublicenses only to the extent permitted by Section 2.1.2) under the Licensed Technology (including the Licensed Patents) to use, sell, have sold, import, have imported or otherwise Commercialize the Licensed Products in the Field in the Territory.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Affiliate License-Licensee_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Licensee shall be entitled to grant sublicenses under its license pursuant to Section 2.1 to Affiliates only, provided that any sublicense granted by Licensee under this Section 2.1.2 shall be made through a written agreement in the English language and shall be consistent with the terms of this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Affiliate License-Licensee_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Licensee shall be entitled to grant sublicenses under its license pursuant to Section 2.1 to Affiliates only, provided that any sublicense granted by Licensee under this Section 2.1.2 shall be made through a written agreement in the English language and shall be consistent with the terms of this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Affiliate License-Licensee_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "For those countries where a specific license is required for a joint owner of a Joint Invention or Joint Improvement to practice such Joint Invention or Joint Improvement, in such country, each Party hereby grants to the other Party a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, under such Party's right, title and interest in and to such Joint Invention or Joint Improvement to freely exploit such Joint Invention or Joint Improvement in such country, subject to the terms and conditions of this Agreement and the licenses granted hereunder.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Affiliate License-Licensee_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "For those countries where a specific license is required for a joint owner of a Joint Invention or Joint Improvement to practice such Joint Invention or Joint Improvement, in such country, each Party hereby grants to the other Party a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, under such Party's right, title and interest in and to such Joint Invention or Joint Improvement to freely exploit such Joint Invention or Joint Improvement in such country, subject to the terms and conditions of this Agreement and the licenses granted hereunder.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Irrevocable Or Perpetual License_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "For those countries where a specific license is required for a joint owner of a Joint Invention or Joint Improvement to practice such Joint Invention or Joint Improvement, in such country, each Party hereby grants to the other Party a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, under such Party's right, title and interest in and to such Joint Invention or Joint Improvement to freely exploit such Joint Invention or Joint Improvement in such country, subject to the terms and conditions of this Agreement and the licenses granted hereunder.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Irrevocable Or Perpetual License_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "For those countries where a specific license is required for a joint owner of a Joint Invention or Joint Improvement to practice such Joint Invention or Joint Improvement, in such country, each Party hereby grants to the other Party a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, under such Party's right, title and interest in and to such Joint Invention or Joint Improvement to freely exploit such Joint Invention or Joint Improvement in such country, subject to the terms and conditions of this Agreement and the licenses granted hereunder.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Irrevocable Or Perpetual License_2",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "Licensee hereby grants to Bioeq during the term of this Agreement (and, subject to Section 15.3.4, after termination",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Irrevocable Or Perpetual License_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "or expiration of this Agreement) a non-exclusive, fully-paid, irrevocable license (including the right to grant sublicenses) under all Intellectual Property Rights and Know-How Controlled by Licensee and embodied within, or claiming or covering the Licensee Improvements, to Develop, Manufacture, sell, import, or otherwise Commercialize Licensed Products outside of the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Irrevocable Or Perpetual License_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "or expiration of this Agreement) a non-exclusive, fully-paid, irrevocable license (including the right to grant sublicenses) under all Intellectual Property Rights and Know-How Controlled by Licensee and embodied within, or claiming or covering the Licensee Improvements, to Develop, Manufacture, sell, import, or otherwise Commercialize Licensed Products outside of the Territory.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Licensee shall, within [***] ([***]) days of the effective date of termination of the Agreement at the latest (and at no cost to Bioeq if this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5, or at Bioeq's cost and expense if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8, as applicable) transfer and assign to Bioeq or its designee all of Licensee's right, title and interest in and to any and all Biologics License Applications and Biologics License Application Approvals controlled by Licensee for the Licensed Products in the Field in the Territory as of the effective date of such termination, including any and all documentation pertaining to such filings and Biologics License Application Approvals (provided that the physical or electronic transfer of files and documentation in connection with such transfer and assignment of rights may occur after such [***] ([***]) day period without being deemed a breach of this Section 15.3.2 by Licensee)",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.29",
          "bbox": [
            2775.0,
            283.0,
            3027.0,
            325.0
          ],
          "confidence": 0.9998047947883606
        },
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            344.0,
            3030.0,
            382.0
          ],
          "confidence": 0.999879777431488
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            404.0,
            3027.0,
            440.0
          ],
          "confidence": 0.999829888343811
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not",
          "bbox": [
            321.0,
            460.0,
            2991.0,
            503.0
          ],
          "confidence": 0.9897100329399109
        },
        {
          "text": "material and would likely cause competitive harm to the registrant if publicly disclosed.",
          "bbox": [
            825.0,
            515.0,
            2478.0,
            559.0
          ],
          "confidence": 0.9881774187088013
        },
        {
          "text": "NOV 02, 2019",
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ],
          "confidence": 0.9989316463470459
        },
        {
          "text": "BIOEQ IP AG",
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ],
          "confidence": 0.998244047164917
        },
        {
          "text": "AND",
          "bbox": [
            1595.0,
            1986.0,
            1715.0,
            2034.0
          ],
          "confidence": 0.9988322257995605
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ],
          "confidence": 0.9984176158905029
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ],
          "confidence": 0.9851366877555847
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9914476871490479
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Licensee shall, within [***] ([***]) days of the effective date of termination of the Agreement at the latest (and at no cost to Bioeq if this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5, or at Bioeq's cost and expense if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8, as applicable) transfer and assign to Bioeq or its designee all of Licensee's right, title and interest in and to any and all Biologics License Applications and Biologics License Application Approvals controlled by Licensee for the Licensed Products in the Field in the Territory as of the effective date of such termination, including any and all documentation pertaining to such filings and Biologics License Application Approvals (provided that the physical or electronic transfer of files and documentation in connection with such transfer and assignment of rights may occur after such [***] ([***]) day period without being deemed a breach of this Section 15.3.2 by Licensee)",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Licensee shall (at no cost to Bioeq if this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5, or at Bioeq's cost and expense if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8, as applicable) use Commercially Reasonable Efforts to cooperate with Bioeq or its designee, and provide [***] reasonable assistance and support, to [***] Bioeq or its designee to take over the Commercialization of the Licensed Products in the Field in the Territory [***] following the effective date of such termination, including by (a) using Commercially Reasonable Efforts to provide [***], (b) disclosing and assigning (to the extent permitted under the relevant agreement) to Bioeq Licensee's existing agreements relating solely to the Commercialization of the Licensed Product in the Territory, including with [***], to the extent legally possible ([***]) and (c) transferring Licensed Product- specific marketing materials, including [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.29",
          "bbox": [
            2775.0,
            283.0,
            3027.0,
            325.0
          ],
          "confidence": 0.9998047947883606
        },
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            344.0,
            3030.0,
            382.0
          ],
          "confidence": 0.999879777431488
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            404.0,
            3027.0,
            440.0
          ],
          "confidence": 0.999829888343811
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not",
          "bbox": [
            321.0,
            460.0,
            2991.0,
            503.0
          ],
          "confidence": 0.9897100329399109
        },
        {
          "text": "material and would likely cause competitive harm to the registrant if publicly disclosed.",
          "bbox": [
            825.0,
            515.0,
            2478.0,
            559.0
          ],
          "confidence": 0.9881774187088013
        },
        {
          "text": "NOV 02, 2019",
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ],
          "confidence": 0.9989316463470459
        },
        {
          "text": "BIOEQ IP AG",
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ],
          "confidence": 0.998244047164917
        },
        {
          "text": "AND",
          "bbox": [
            1595.0,
            1986.0,
            1715.0,
            2034.0
          ],
          "confidence": 0.9988322257995605
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ],
          "confidence": 0.9984176158905029
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ],
          "confidence": 0.9851366877555847
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9914476871490479
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Licensee shall (at no cost to Bioeq if this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5, or at Bioeq's cost and expense if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8, as applicable) use Commercially Reasonable Efforts to cooperate with Bioeq or its designee, and provide [***] reasonable assistance and support, to [***] Bioeq or its designee to take over the Commercialization of the Licensed Products in the Field in the Territory [***] following the effective date of such termination, including by (a) using Commercially Reasonable Efforts to provide [***], (b) disclosing and assigning (to the extent permitted under the relevant agreement) to Bioeq Licensee's existing agreements relating solely to the Commercialization of the Licensed Product in the Territory, including with [***], to the extent legally possible ([***]) and (c) transferring Licensed Product- specific marketing materials, including [***].",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Licensee shall be permitted, at Bioeq's choice (if this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5) or at Licensee's choice (if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8), to cither (a) continue selling its and its Affiliates' inventory of Licensed Products existing on the termination effective date in accordance with this Agreement for a maximum period of [***] ([***]) days (in which case all terms and conditions of this Agreement, including Licensee's obligation to report and pay royalties, shall continue to apply to such continued sale) or (b) sell such inventory to Bioeq at the supply price paid by Licensee to Bioeq for such inventory in accordance with the Manufacturing and Supply Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.29",
          "bbox": [
            2775.0,
            283.0,
            3027.0,
            325.0
          ],
          "confidence": 0.9998047947883606
        },
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            344.0,
            3030.0,
            382.0
          ],
          "confidence": 0.999879777431488
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            404.0,
            3027.0,
            440.0
          ],
          "confidence": 0.999829888343811
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not",
          "bbox": [
            321.0,
            460.0,
            2991.0,
            503.0
          ],
          "confidence": 0.9897100329399109
        },
        {
          "text": "material and would likely cause competitive harm to the registrant if publicly disclosed.",
          "bbox": [
            825.0,
            515.0,
            2478.0,
            559.0
          ],
          "confidence": 0.9881774187088013
        },
        {
          "text": "NOV 02, 2019",
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ],
          "confidence": 0.9989316463470459
        },
        {
          "text": "BIOEQ IP AG",
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ],
          "confidence": 0.998244047164917
        },
        {
          "text": "AND",
          "bbox": [
            1595.0,
            1986.0,
            1715.0,
            2034.0
          ],
          "confidence": 0.9988322257995605
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ],
          "confidence": 0.9984176158905029
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ],
          "confidence": 0.9851366877555847
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9914476871490479
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "NOV 02, 2019",
          "page": 0,
          "bbox": [
            1488.0,
            1188.0,
            1818.0,
            1241.0
          ]
        },
        {
          "text": "BIOEQ IP AG",
          "page": 0,
          "bbox": [
            1492.0,
            1873.0,
            1820.0,
            1917.0
          ]
        },
        {
          "text": "COHERUS BIOSCIENCES, INC",
          "page": 0,
          "bbox": [
            1265.0,
            2101.0,
            2039.0,
            2143.0
          ]
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1077.0,
            2514.0,
            2226.0,
            2551.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Licensee shall be permitted, at Bioeq's choice (if this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5) or at Licensee's choice (if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8), to cither (a) continue selling its and its Affiliates' inventory of Licensed Products existing on the termination effective date in accordance with this Agreement for a maximum period of [***] ([***]) days (in which case all terms and conditions of this Agreement, including Licensee's obligation to report and pay royalties, shall continue to apply to such continued sale) or (b) sell such inventory to Bioeq at the supply price paid by Licensee to Bioeq for such inventory in accordance with the Manufacturing and Supply Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Audit Rights_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon reasonable written request of Bioeq, and no more than once during a given calendar year, Licensee shall make all records reasonably necessary to verify the accuracy of its quarterly reports pursuant to Section 7.3.2 available for inspection by an independent auditor of an internationally recognized auditing firm during Licensee's standard business hours. Such audit shall be for the purpose of ensuring Licensee's compliance with its payment obligations hereunder only.",
      "page_number": 4,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9777219891548157
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3025.0,
            384.0
          ],
          "confidence": 0.9990074038505554
        },
        {
          "text": "(b)",
          "bbox": [
            486.0,
            406.0,
            542.0,
            451.0
          ],
          "confidence": 0.9973199963569641
        },
        {
          "text": "the Licensee enters into a merger, consolidation or similar transaction with a Competitor (whether or not.",
          "bbox": [
            870.0,
            402.0,
            3025.0,
            450.0
          ],
          "confidence": 0.9922320246696472
        },
        {
          "text": "such Party is the surviving entity) and as a result of such merger, consolidation or similar transaction (i) the managing directors or the.",
          "bbox": [
            281.0,
            470.0,
            3027.0,
            513.0
          ],
          "confidence": 0.9920163750648499
        },
        {
          "text": "members of the Board of Directors of the Licensee immediately prior to such transaction constitute less than a majority of the",
          "bbox": [
            277.0,
            530.0,
            3025.0,
            576.0
          ],
          "confidence": 0.9923511743545532
        },
        {
          "text": "managing directors or the members of the Board of Directors of the Licensee or such surviving person immediately following such",
          "bbox": [
            277.0,
            594.0,
            3027.0,
            643.0
          ],
          "confidence": 0.9862891435623169
        },
        {
          "text": "transaction or (ii) the persons that beneficially owned, directly or indirectly, the shares of Voting Stock of the Licensee immediately",
          "bbox": [
            277.0,
            656.0,
            3023.0,
            704.0
          ],
          "confidence": 0.9987921714782715
        },
        {
          "text": "prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of the Licensee representing a",
          "bbox": [
            275.0,
            718.0,
            3031.0,
            769.0
          ],
          "confidence": 0.9947993159294128
        },
        {
          "text": "majority of the total voting power of all outstanding classes of Voting Stock of the surviving person in substantially the same",
          "bbox": [
            279.0,
            786.0,
            3027.0,
            830.0
          ],
          "confidence": 0.9937988519668579
        },
        {
          "text": "proportions as their ownership of Voting Stock of the Licensee immediately prior to such transaction.",
          "bbox": [
            277.0,
            844.0,
            2342.0,
            895.0
          ],
          "confidence": 0.9985789060592651
        },
        {
          "text": "1.14",
          "bbox": [
            480.0,
            961.0,
            589.0,
            1009.0
          ],
          "confidence": 0.9999711513519287
        },
        {
          "text": "Confidential Information means, with respect to a Party, all Know-How and all other proprietary information.",
          "bbox": [
            754.0,
            967.0,
            3025.0,
            1011.0
          ],
          "confidence": 0.9920302629470825
        },
        {
          "text": "of such Party, including information on the business, affairs, research and development activities, results of non-clinical and clinical.",
          "bbox": [
            281.0,
            1031.0,
            3027.0,
            1074.0
          ],
          "confidence": 0.989547848701477
        },
        {
          "text": "trials, national and multinational regulatory proceedings and affairs, finances, plans, contractual relationships and operations of such.",
          "bbox": [
            281.0,
            1095.0,
            3025.0,
            1138.0
          ],
          "confidence": 0.9868026971817017
        },
        {
          "text": "Party. Furthermore, the terms and conditions of this Agreement shall be considered Confidential Information of both Parties. For the",
          "bbox": [
            281.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9930081367492676
        },
        {
          "text": "avoidance of doubt, all Know-How and proprietary information relating to the Licensed Products generated by or on behalf of Bioeq.",
          "bbox": [
            277.0,
            1217.0,
            3027.0,
            1265.0
          ],
          "confidence": 0.989470362663269
        },
        {
          "text": "and provided to Licensee hereunder shall be considered Confidential Information of Bioeq.",
          "bbox": [
            279.0,
            1277.0,
            2128.0,
            1330.0
          ],
          "confidence": 0.9949022531509399
        },
        {
          "text": "1.15",
          "bbox": [
            480.0,
            1396.0,
            589.0,
            1444.0
          ],
          "confidence": 0.9999708533287048
        },
        {
          "text": "Control (whether used as a noun or as a verb) or Controlled means, with respect to any Intellectual Property",
          "bbox": [
            752.0,
            1396.0,
            3025.0,
            1451.0
          ],
          "confidence": 0.9984130859375
        },
        {
          "text": "Right, Trademark or Know-How, the possession (whether by ownership or license, other than pursuant to this Agreement) by a Party",
          "bbox": [
            277.0,
            1462.0,
            3023.0,
            1513.0
          ],
          "confidence": 0.9943523406982422
        },
        {
          "text": "of the ability to grant to the other Party access or a license as provided herein under such Intellectual Property Right, Trademark or",
          "bbox": [
            281.0,
            1529.0,
            3027.0,
            1573.0
          ],
          "confidence": 0.9949034452438354
        },
        {
          "text": "Know-How without violating the terms of any agreement or other arrangements with any Third Party.",
          "bbox": [
            279.0,
            1590.0,
            2369.0,
            1637.0
          ],
          "confidence": 0.9864059686660767
        },
        {
          "text": "1.16",
          "bbox": [
            478.0,
            1698.0,
            591.0,
            1752.0
          ],
          "confidence": 0.9999558925628662
        },
        {
          "text": "Damages shall have the meaning ascribed to it in Section 9.4.3..",
          "bbox": [
            750.0,
            1701.0,
            2059.0,
            1752.0
          ],
          "confidence": 0.9965372681617737
        },
        {
          "text": "1.17",
          "bbox": [
            478.0,
            1818.0,
            591.0,
            1871.0
          ],
          "confidence": 0.9999223351478577
        },
        {
          "text": "Defend or Defense shall have the meaning ascribed to it in Section 9.4.2..",
          "bbox": [
            750.0,
            1820.0,
            2258.0,
            1871.0
          ],
          "confidence": 0.9893102049827576
        },
        {
          "text": "1.18",
          "bbox": [
            478.0,
            1937.0,
            591.0,
            1990.0
          ],
          "confidence": 0.9999673366546631
        },
        {
          "text": "Development means all non-clinical and clinical research and drug development activities as well as.",
          "bbox": [
            754.0,
            1944.0,
            3025.0,
            1988.0
          ],
          "confidence": 0.9888492822647095
        },
        {
          "text": "Manufacturing process development, upscaling of the Manufacturing process and chemistry, manufacturing and control development",
          "bbox": [
            279.0,
            2006.0,
            3027.0,
            2052.0
          ],
          "confidence": 0.9937490820884705
        },
        {
          "text": "work conducted in respect of any pharmaceutical product, including those necessary to obtain Regulatory Approval for such",
          "bbox": [
            281.0,
            2072.0,
            3027.0,
            2116.0
          ],
          "confidence": 0.9899325370788574
        },
        {
          "text": "pharmaceutical product. When used as a verb, Develop means to engage in Development.",
          "bbox": [
            279.0,
            2134.0,
            2148.0,
            2186.0
          ],
          "confidence": 0.9984303712844849
        },
        {
          "text": "1.19",
          "bbox": [
            478.0,
            2246.0,
            589.0,
            2299.0
          ],
          "confidence": 0.9999583959579468
        },
        {
          "text": "Disclosing Party shall have the meaning ascribed to it in Section 11.1.",
          "bbox": [
            752.0,
            2251.0,
            2195.0,
            2301.0
          ],
          "confidence": 0.9872499704360962
        },
        {
          "text": "1.20",
          "bbox": [
            478.0,
            2366.0,
            585.0,
            2414.0
          ],
          "confidence": 0.9999449253082275
        },
        {
          "text": "Effective Date shall have the meaning ascribed to it in the introductory paragraph above",
          "bbox": [
            752.0,
            2368.0,
            2572.0,
            2418.0
          ],
          "confidence": 0.9994855523109436
        },
        {
          "text": "1.21",
          "bbox": [
            478.0,
            2485.0,
            587.0,
            2538.0
          ],
          "confidence": 0.9999347925186157
        },
        {
          "text": "Existing Reference Product shall have the meaning ascribed to it in Section 1.61..",
          "bbox": [
            750.0,
            2487.0,
            2443.0,
            2538.0
          ],
          "confidence": 0.9832090735435486
        },
        {
          "text": "1.22",
          "bbox": [
            478.0,
            2600.0,
            589.0,
            2653.0
          ],
          "confidence": 0.9999254941940308
        },
        {
          "text": "FDA means the United States Food and Drug Administration, and any successor agency thereto",
          "bbox": [
            750.0,
            2602.0,
            2737.0,
            2655.0
          ],
          "confidence": 0.991290807723999
        },
        {
          "text": "1.23",
          "bbox": [
            480.0,
            2721.0,
            587.0,
            2768.0
          ],
          "confidence": 0.9999662041664124
        },
        {
          "text": "Field means any human use of the Licensed Product in the field of ophthalmology and for any other approved",
          "bbox": [
            749.0,
            2719.0,
            3029.0,
            2778.0
          ],
          "confidence": 0.9872778654098511
        },
        {
          "text": "labelled indication of such Licensed Products..",
          "bbox": [
            281.0,
            2789.0,
            1209.0,
            2831.0
          ],
          "confidence": 0.9907771944999695
        },
        {
          "text": "1.24",
          "bbox": [
            478.0,
            2900.0,
            589.0,
            2955.0
          ],
          "confidence": 0.9999393224716187
        },
        {
          "text": "First Commercial Sale means, with respect to any Licensed Product in the Territory, the first sale by",
          "bbox": [
            750.0,
            2904.0,
            3025.0,
            2957.0
          ],
          "confidence": 0.9871525764465332
        },
        {
          "text": "Licensee or its Affiliates of such Licensed Product to a Third Party for use in the Field in the Territory, after such Licensed Product.",
          "bbox": [
            277.0,
            2969.0,
            3027.0,
            3015.0
          ],
          "confidence": 0.9941776394844055
        },
        {
          "text": "has been granted Regulatory Approval for use in the Field in the Territory..",
          "bbox": [
            277.0,
            3033.0,
            1793.0,
            3083.0
          ],
          "confidence": 0.9928413033485413
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9924864768981934
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Audit Rights_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon reasonable written request of Bioeq, and no more than once during a given calendar year, Licensee shall make all records reasonably necessary to verify the accuracy of its quarterly reports pursuant to Section 7.3.2 available for inspection by an independent auditor of an internationally recognized auditing firm during Licensee's standard business hours. Such audit shall be for the purpose of ensuring Licensee's compliance with its payment obligations hereunder only.",
      "page_number": 5,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9946516156196594
        },
        {
          "text": "Execution Version",
          "bbox": [
            2673.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.9944149255752563
        },
        {
          "text": "1.25",
          "bbox": [
            478.0,
            400.0,
            591.0,
            455.0
          ],
          "confidence": 0.9998903274536133
        },
        {
          "text": "[***] means [***]",
          "bbox": [
            754.0,
            406.0,
            1138.0,
            457.0
          ],
          "confidence": 0.9976882934570312
        },
        {
          "text": "1.26",
          "bbox": [
            477.0,
            515.0,
            589.0,
            568.0
          ],
          "confidence": 0.9999468326568604
        },
        {
          "text": "[***] Agreement means the license agreement existing between Bioeq and [***] dated as of [***] and.",
          "bbox": [
            754.0,
            521.0,
            3027.0,
            570.0
          ],
          "confidence": 0.9868119359016418
        },
        {
          "text": "attached to this Agreement as Annex 1.",
          "bbox": [
            281.0,
            588.0,
            1093.0,
            632.0
          ],
          "confidence": 0.9994781613349915
        },
        {
          "text": "1.27",
          "bbox": [
            478.0,
            700.0,
            589.0,
            753.0
          ],
          "confidence": 0.9999474287033081
        },
        {
          "text": "Gross Margin means Net Sales for the sale of any Licensed Product less (a) [***] the supply price paid by.",
          "bbox": [
            750.0,
            700.0,
            3025.0,
            758.0
          ],
          "confidence": 0.9853644967079163
        },
        {
          "text": "Licensee or its Affiliates to Bioeq for the supply of such Licensed Product under the Manufacturing and Supply Agreement (including",
          "bbox": [
            274.0,
            766.0,
            3025.0,
            819.0
          ],
          "confidence": 0.9881497621536255
        },
        {
          "text": "any Sales Tax thereon paid by Licensee to Bioeq and not refunded back to Licensee in accordance with Section 8.1) [***], (b)",
          "bbox": [
            279.0,
            830.0,
            3025.0,
            881.0
          ],
          "confidence": 0.9930264949798584
        },
        {
          "text": "Damages, and (c) Qualifying IP Clearance Litigation Costs. Gross Margin will be calculated on a Licensed Product-by-Licensed",
          "bbox": [
            279.0,
            897.0,
            3027.0,
            941.0
          ],
          "confidence": 0.9966676235198975
        },
        {
          "text": "Product and calendar quarter-by-calendar quarter basis in accordance with Section 7.3.3.",
          "bbox": [
            275.0,
            954.0,
            2112.0,
            1005.0
          ],
          "confidence": 0.9974932074546814
        },
        {
          "text": "1.28",
          "bbox": [
            478.0,
            1069.0,
            589.0,
            1122.0
          ],
          "confidence": 0.9999539852142334
        },
        {
          "text": "Improvement means any Invention developed, conceived or reduced to practice by or on behalf of either.",
          "bbox": [
            750.0,
            1073.0,
            3025.0,
            1120.0
          ],
          "confidence": 0.9959661960601807
        },
        {
          "text": "Party in relation to any Licensed Product during the term of this Agreement, but for clarity excluding any New Products.",
          "bbox": [
            277.0,
            1135.0,
            2750.0,
            1186.0
          ],
          "confidence": 0.9957283139228821
        },
        {
          "text": "1.29",
          "bbox": [
            476.0,
            1246.0,
            590.0,
            1304.0
          ],
          "confidence": 0.9999220371246338
        },
        {
          "text": "Indemnified Party shall have the meaning ascribed to it in Section 13.3(a).",
          "bbox": [
            750.0,
            1255.0,
            2298.0,
            1305.0
          ],
          "confidence": 0.9983393549919128
        },
        {
          "text": "1.30",
          "bbox": [
            478.0,
            1371.0,
            585.0,
            1418.0
          ],
          "confidence": 0.9999824166297913
        },
        {
          "text": "Indemnifying Party shall have the meaning ascribed to it in Section 13.3(a).",
          "bbox": [
            752.0,
            1378.0,
            2324.0,
            1422.0
          ],
          "confidence": 0.9942663908004761
        },
        {
          "text": "1.31",
          "bbox": [
            480.0,
            1487.0,
            585.0,
            1535.0
          ],
          "confidence": 0.9999938011169434
        },
        {
          "text": "Infringement Claim shall have the meaning ascribed to it in Section 9.4.2.",
          "bbox": [
            752.0,
            1487.0,
            2287.0,
            1539.0
          ],
          "confidence": 0.9950664639472961
        },
        {
          "text": "1.32",
          "bbox": [
            476.0,
            1600.0,
            590.0,
            1658.0
          ],
          "confidence": 0.9999843835830688
        },
        {
          "text": "Insolvency Event means:.",
          "bbox": [
            752.0,
            1612.0,
            1283.0,
            1656.0
          ],
          "confidence": 0.9760249257087708
        },
        {
          "text": "1.32.1",
          "bbox": [
            480.0,
            1727.0,
            624.0,
            1773.0
          ],
          "confidence": 0.9999870657920837
        },
        {
          "text": "In relation to Licensee: (a) the making by it of a general assignment for the benefit of creditors; (b) the.",
          "bbox": [
            790.0,
            1729.0,
            3025.0,
            1778.0
          ],
          "confidence": 0.9810162782669067
        },
        {
          "text": "commencement by it of any voluntary petition in bankruptcy or suffering by it of the filing of an involuntary petition of its creditors; (c)",
          "bbox": [
            279.0,
            1796.0,
            3023.0,
            1840.0
          ],
          "confidence": 0.9899019598960876
        },
        {
          "text": "the suffering by it of the appointment of a receiver to take possession of all, or substantially all, of its assets; (d) the suffering by it of.",
          "bbox": [
            281.0,
            1858.0,
            3030.0,
            1902.0
          ],
          "confidence": 0.9881004691123962
        },
        {
          "text": "the attachment or other judicial seizure of all, or substantially all, of its assets; (e) the admission by it in writing of its inability to pay its",
          "bbox": [
            279.0,
            1919.0,
            3025.0,
            1964.0
          ],
          "confidence": 0.9946365356445312
        },
        {
          "text": "debts as they come due; or (f) the making by it of an offer of settlement, extension or composition to its creditors generally..",
          "bbox": [
            277.0,
            1979.0,
            2795.0,
            2032.0
          ],
          "confidence": 0.9876922965049744
        },
        {
          "text": "1.32.2",
          "bbox": [
            482.0,
            2096.0,
            627.0,
            2142.0
          ],
          "confidence": 0.9999907612800598
        },
        {
          "text": "In relation to Bioeq: (a) its over-indebtedness (Uberschuldung), (b) its inability to make payments as and",
          "bbox": [
            787.0,
            2090.0,
            3032.0,
            2151.0
          ],
          "confidence": 0.9952173233032227
        },
        {
          "text": "when they fall due (Zahlungsunfahigkeit), (c) it ceasing to make payments on account of debts as and when they fall due.",
          "bbox": [
            281.0,
            2164.0,
            3025.0,
            2207.0
          ],
          "confidence": 0.9882230162620544
        },
        {
          "text": "(Zahlungseinstellung), (d) the commencement of negotiations with its creditors with a view to rescheduling its indebtedness, (e) the.",
          "bbox": [
            281.0,
            2228.0,
            3025.0,
            2271.0
          ],
          "confidence": 0.9967859983444214
        },
        {
          "text": "initiation by Bioeq of any proceedings for bankruptcy (Konkurs), the postponement of bankruptcy (Konkursaufschub) or the grant.",
          "bbox": [
            277.0,
            2286.0,
            3029.0,
            2337.0
          ],
          "confidence": 0.9915153980255127
        },
        {
          "text": "of a composition moratorium (Nachlassstundung), (f) the opening of proceedings for bankruptcy, the postponement of bankruptcy or.",
          "bbox": [
            281.0,
            2354.0,
            3025.0,
            2397.0
          ],
          "confidence": 0.9971796274185181
        },
        {
          "text": "the grant of a composition moratorium with respect to Bioeq upon request of a Third Party (g) the sequestration (Arrestierung),.",
          "bbox": [
            277.0,
            2412.0,
            3025.0,
            2463.0
          ],
          "confidence": 0.998443603515625
        },
        {
          "text": "occurrence of any event which is similar in its effect to (a) through (f) under any Applicable Laws..",
          "bbox": [
            277.0,
            2540.0,
            2306.0,
            2586.0
          ],
          "confidence": 0.9869463443756104
        },
        {
          "text": "1.33",
          "bbox": [
            480.0,
            2655.0,
            585.0,
            2703.0
          ],
          "confidence": 0.9999943971633911
        },
        {
          "text": "Intellectual Property Rights means, with respect to any technology, (a) all Patent Rights which claim or.",
          "bbox": [
            752.0,
            2661.0,
            3027.0,
            2704.0
          ],
          "confidence": 0.993728756904602
        },
        {
          "text": "cover such technology, and (b) all other existing and future intellectual property rights (but not any Know-How) relating to such.",
          "bbox": [
            277.0,
            2723.0,
            3027.0,
            2772.0
          ],
          "confidence": 0.9932931661605835
        },
        {
          "text": "technology, including all legally protected trade secrets, copyrights and other intellectual property rights of any kind, but excluding any",
          "bbox": [
            277.0,
            2785.0,
            3023.0,
            2836.0
          ],
          "confidence": 0.9925726056098938
        },
        {
          "text": "Trademark.",
          "bbox": [
            281.0,
            2851.0,
            515.0,
            2889.0
          ],
          "confidence": 0.999904990196228
        },
        {
          "text": "1.34",
          "bbox": [
            477.0,
            2962.0,
            589.0,
            3015.0
          ],
          "confidence": 0.9999886751174927
        },
        {
          "text": "In-Licensed Licensed Patents means all Licensed Patents which are exclusively in-licensed by Bioeq,.",
          "bbox": [
            747.0,
            2958.0,
            3027.0,
            3022.0
          ],
          "confidence": 0.996616542339325
        },
        {
          "text": "including those Patent Rights exclusively in-licensed by Bioeq from [***] pursuant to the [***] Agreement ([***]-Licensed Patents)..",
          "bbox": [
            283.0,
            3032.0,
            3000.0,
            3075.0
          ],
          "confidence": 0.9832793474197388
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4435.0,
            1437.0,
            4477.0
          ],
          "confidence": 0.98760586977005
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Uncapped Liability_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a partyâs liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "Except for a breach of Section 11 (\"Confidentiality\"), and without limiting a Party's indemnification obligations hereunder, in no event shall either Party be liable to the other Party in any manner for any special, non- compensatory, consequential, indirect, incidental, statutory or punitive damages of any kind, including lost profits and lost revenue, regardless of the form of action, whether in contract, tort, product liability or otherwise, even if informed of or aware of the possibility of any such damages in advance, except to the extent that such limitation of liability is contrary to the Applicable Law or any such special, non-compensatory, consequential, indirect, incidental, statutory or punitive damages have been awarded to a Third Party under a Third Party Claim.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Uncapped Liability_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a partyâs liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "Except for a breach of Section 11 (\"Confidentiality\"), and without limiting a Party's indemnification obligations hereunder, in no event shall either Party be liable to the other Party in any manner for any special, non- compensatory, consequential, indirect, incidental, statutory or punitive damages of any kind, including lost profits and lost revenue, regardless of the form of action, whether in contract, tort, product liability or otherwise, even if informed of or aware of the possibility of any such damages in advance, except to the extent that such limitation of liability is contrary to the Applicable Law or any such special, non-compensatory, consequential, indirect, incidental, statutory or punitive damages have been awarded to a Third Party under a Third Party Claim.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Cap On Liability_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "Except for a breach of Section 11 (\"Confidentiality\"), and without limiting a Party's indemnification obligations hereunder, in no event shall either Party be liable to the other Party in any manner for any special, non- compensatory, consequential, indirect, incidental, statutory or punitive damages of any kind, including lost profits and lost revenue, regardless of the form of action, whether in contract, tort, product liability or otherwise, even if informed of or aware of the possibility of any such damages in advance, except to the extent that such limitation of liability is contrary to the Applicable Law or any such special, non-compensatory, consequential, indirect, incidental, statutory or punitive damages have been awarded to a Third Party under a Third Party Claim.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Cap On Liability_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "Except for a breach of Section 11 (\"Confidentiality\"), and without limiting a Party's indemnification obligations hereunder, in no event shall either Party be liable to the other Party in any manner for any special, non- compensatory, consequential, indirect, incidental, statutory or punitive damages of any kind, including lost profits and lost revenue, regardless of the form of action, whether in contract, tort, product liability or otherwise, even if informed of or aware of the possibility of any such damages in advance, except to the extent that such limitation of liability is contrary to the Applicable Law or any such special, non-compensatory, consequential, indirect, incidental, statutory or punitive damages have been awarded to a Third Party under a Third Party Claim.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Covenant Not To Sue_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterpartyâs ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "Bioeq may terminate this Agreement immediately upon written notice to Licensee, if Licensee or any of its Affiliates or sublicensees directly or indirectly challenge the validity or enforceability of, or oppose any extension of or the grant of a supplementary protection certificate with respect to, any Licensed Patent in any legal, court, administrative or other governmental proceeding.",
      "page_number": 1,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2784.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3023.0,
            384.0
          ],
          "confidence": 0.999701201915741
        },
        {
          "text": "CONTENTS",
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ],
          "confidence": 0.9988241195678711
        },
        {
          "text": "Clause",
          "bbox": [
            275.0,
            519.0,
            439.0,
            570.0
          ],
          "confidence": 0.99983149766922
        },
        {
          "text": "Page",
          "bbox": [
            609.0,
            530.0,
            705.0,
            563.0
          ],
          "confidence": 0.9989874958992004
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            663.0,
            326.0,
            713.0
          ],
          "confidence": 0.9998822808265686
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ],
          "confidence": 0.9983311295509338
        },
        {
          "text": "2.",
          "bbox": [
            268.0,
            780.0,
            328.0,
            835.0
          ],
          "confidence": 0.9999294877052307
        },
        {
          "text": "LICENSE GRANT10",
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ],
          "confidence": 0.999794065952301
        },
        {
          "text": "3.",
          "bbox": [
            270.0,
            901.0,
            326.0,
            950.0
          ],
          "confidence": 0.9999774098396301
        },
        {
          "text": "DEVELOPMENT11",
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ],
          "confidence": 0.9985255599021912
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1020.0,
            326.0,
            1071.0
          ],
          "confidence": 0.999610424041748
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ],
          "confidence": 0.9998011589050293
        },
        {
          "text": "5.",
          "bbox": [
            272.0,
            1138.0,
            326.0,
            1190.0
          ],
          "confidence": 0.8245011568069458
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ],
          "confidence": 0.9987892508506775
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            1259.0,
            326.0,
            1310.0
          ],
          "confidence": 0.9998369216918945
        },
        {
          "text": "COMMERCIALIZATION18",
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ],
          "confidence": 0.9990432262420654
        },
        {
          "text": "7.",
          "bbox": [
            270.0,
            1374.0,
            328.0,
            1431.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ],
          "confidence": 0.9991937875747681
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            1497.0,
            326.0,
            1548.0
          ],
          "confidence": 0.9999840259552002
        },
        {
          "text": "TAXATION23",
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ],
          "confidence": 0.998888373374939
        },
        {
          "text": "9.",
          "bbox": [
            272.0,
            1615.0,
            326.0,
            1667.0
          ],
          "confidence": 0.7600966095924377
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ],
          "confidence": 0.9991966485977173
        },
        {
          "text": "10.",
          "bbox": [
            274.0,
            1736.0,
            353.0,
            1787.0
          ],
          "confidence": 0.9999274611473083
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ],
          "confidence": 0.9895986318588257
        },
        {
          "text": "11.",
          "bbox": [
            274.0,
            1855.0,
            352.0,
            1906.0
          ],
          "confidence": 0.8803178668022156
        },
        {
          "text": "CONFIDENTIALITY30",
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ],
          "confidence": 0.9988167881965637
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1974.0,
            353.0,
            2025.0
          ],
          "confidence": 0.9999602437019348
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ],
          "confidence": 0.9907991886138916
        },
        {
          "text": "13.",
          "bbox": [
            274.0,
            2094.0,
            353.0,
            2143.0
          ],
          "confidence": 0.9999868273735046
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ],
          "confidence": 0.9978808164596558
        },
        {
          "text": "14.",
          "bbox": [
            274.0,
            2213.0,
            353.0,
            2262.0
          ],
          "confidence": 0.9999709129333496
        },
        {
          "text": "GOVERNANCE35",
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ],
          "confidence": 0.9992990493774414
        },
        {
          "text": "15.",
          "bbox": [
            274.0,
            2330.0,
            352.0,
            2383.0
          ],
          "confidence": 0.9999801516532898
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ],
          "confidence": 0.9934631586074829
        },
        {
          "text": "16.",
          "bbox": [
            274.0,
            2450.0,
            353.0,
            2502.0
          ],
          "confidence": 0.9999613761901855
        },
        {
          "text": "GENERAL PROVISIONS43",
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ],
          "confidence": 0.9994773864746094
        },
        {
          "text": "Schedules",
          "bbox": [
            275.0,
            2543.0,
            510.0,
            2593.0
          ],
          "confidence": 0.9757716655731201
        },
        {
          "text": "Annex 1: [***] Agreement",
          "bbox": [
            277.0,
            2655.0,
            899.0,
            2706.0
          ],
          "confidence": 0.9960880875587463
        },
        {
          "text": "Annex 2: Term Sheet for Manufacturing and Supply Agreement",
          "bbox": [
            277.0,
            2772.0,
            1726.0,
            2823.0
          ],
          "confidence": 0.9927083253860474
        },
        {
          "text": "Schedule 1.36: Licensed Patents.",
          "bbox": [
            279.0,
            2891.0,
            1024.0,
            2931.0
          ],
          "confidence": 0.9807108640670776
        },
        {
          "text": "Schedule 3.2: Initial Development & Manufacturing Plan",
          "bbox": [
            277.0,
            3000.0,
            1571.0,
            3048.0
          ],
          "confidence": 0.9972376227378845
        },
        {
          "text": "Schedule 3.5.1: [***]",
          "bbox": [
            279.0,
            3119.0,
            761.0,
            3163.0
          ],
          "confidence": 0.9982419610023499
        },
        {
          "text": "Schedule 6.2(c): Initial Commercialization Commitments",
          "bbox": [
            279.0,
            3234.0,
            1570.0,
            3276.0
          ],
          "confidence": 0.9835025072097778
        },
        {
          "text": "Schedule 6.3: Contents of Commercialization Plan for Planned Activities",
          "bbox": [
            279.0,
            3346.0,
            1925.0,
            3388.0
          ],
          "confidence": 0.9974568486213684
        },
        {
          "text": "Schedule 16.5: Pre-Approved Subcontractors",
          "bbox": [
            277.0,
            3461.0,
            1310.0,
            3507.0
          ],
          "confidence": 0.9994277954101562
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9929704070091248
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONTENTS",
          "page": 1,
          "bbox": [
            1510.0,
            406.0,
            1802.0,
            450.0
          ]
        },
        {
          "text": "DEFINITIONS AND INTERPRETATION1",
          "page": 1,
          "bbox": [
            469.0,
            669.0,
            1461.0,
            705.0
          ]
        },
        {
          "text": "LICENSE GRANT10",
          "page": 1,
          "bbox": [
            466.0,
            786.0,
            957.0,
            828.0
          ]
        },
        {
          "text": "DEVELOPMENT11",
          "page": 1,
          "bbox": [
            469.0,
            906.0,
            930.0,
            943.0
          ]
        },
        {
          "text": "REGULATORY ACTIVITIES14",
          "page": 1,
          "bbox": [
            468.0,
            1023.0,
            1211.0,
            1065.0
          ]
        },
        {
          "text": "MANUFACTURING AND SUPPLY17",
          "page": 1,
          "bbox": [
            469.0,
            1146.0,
            1339.0,
            1182.0
          ]
        },
        {
          "text": "COMMERCIALIZATION18",
          "page": 1,
          "bbox": [
            471.0,
            1265.0,
            1138.0,
            1301.0
          ]
        },
        {
          "text": "FINANCIAL PROVISIONS20",
          "page": 1,
          "bbox": [
            468.0,
            1381.0,
            1160.0,
            1424.0
          ]
        },
        {
          "text": "TAXATION23",
          "page": 1,
          "bbox": [
            468.0,
            1502.0,
            798.0,
            1540.0
          ]
        },
        {
          "text": "INTELLECTUAL PROPERTY24",
          "page": 1,
          "bbox": [
            468.0,
            1623.0,
            1238.0,
            1659.0
          ]
        },
        {
          "text": "COVENANTS RELATING TO THE J***] AGREEMENT30",
          "page": 1,
          "bbox": [
            469.0,
            1740.0,
            1856.0,
            1782.0
          ]
        },
        {
          "text": "CONFIDENTIALITY30",
          "page": 1,
          "bbox": [
            471.0,
            1860.0,
            1028.0,
            1897.0
          ]
        },
        {
          "text": "REPRESENTATIONS. WARRANTIES AND COVENANTS32",
          "page": 1,
          "bbox": [
            469.0,
            1981.0,
            1887.0,
            2017.0
          ]
        },
        {
          "text": "INDEMNIFICATION AND LIMITATION OF LIABILITY34",
          "page": 1,
          "bbox": [
            469.0,
            2100.0,
            1887.0,
            2136.0
          ]
        },
        {
          "text": "GOVERNANCE35",
          "page": 1,
          "bbox": [
            469.0,
            2217.0,
            901.0,
            2255.0
          ]
        },
        {
          "text": "TERM AND TERMINATION: NON-SOLICITATION37",
          "page": 1,
          "bbox": [
            469.0,
            2339.0,
            1774.0,
            2376.0
          ]
        },
        {
          "text": "GENERAL PROVISIONS43",
          "page": 1,
          "bbox": [
            469.0,
            2454.0,
            1116.0,
            2496.0
          ]
        }
      ]
    },
    {
      "id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement__Covenant Not To Sue_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterpartyâs ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "Bioeq may terminate this Agreement immediately upon written notice to Licensee, if Licensee or any of its Affiliates or sublicensees directly or indirectly challenge the validity or enforceability of, or oppose any extension of or the grant of a supplementary protection certificate with respect to, any Licensed Patent in any legal, court, administrative or other governmental proceeding.",
      "page_number": 2,
      "words": [
        {
          "text": "Confidential",
          "bbox": [
            2782.0,
            285.0,
            3030.0,
            329.0
          ],
          "confidence": 0.9953513741493225
        },
        {
          "text": "Execution Version",
          "bbox": [
            2675.0,
            347.0,
            3027.0,
            384.0
          ],
          "confidence": 0.999679446220398
        },
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ],
          "confidence": 0.9964898824691772
        },
        {
          "text": "This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is entered into effective as of Nov. 02, 2019",
          "bbox": [
            486.0,
            521.0,
            3025.0,
            570.0
          ],
          "confidence": 0.9912195205688477
        },
        {
          "text": "(the Effective Date) by and between Bioeg IP AG, having its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,",
          "bbox": [
            283.0,
            592.0,
            3029.0,
            636.0
          ],
          "confidence": 0.9876054525375366
        },
        {
          "text": "having its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee).",
          "bbox": [
            279.0,
            656.0,
            2730.0,
            705.0
          ],
          "confidence": 0.9941772818565369
        },
        {
          "text": "Bioeq and Licensee shall also each individually be referred to herein as a Party, and shall be referred to jointly as the.",
          "bbox": [
            484.0,
            771.0,
            3025.0,
            820.0
          ],
          "confidence": 0.9893651008605957
        },
        {
          "text": "Parties.",
          "bbox": [
            271.0,
            833.0,
            448.0,
            888.0
          ],
          "confidence": 0.9999374151229858
        },
        {
          "text": "RECITALS",
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ],
          "confidence": 0.9993951320648193
        },
        {
          "text": "WHEREAS, Bioeq is a specialized biosimilar company;.",
          "bbox": [
            487.0,
            1060.0,
            1620.0,
            1118.0
          ],
          "confidence": 0.9898350238800049
        },
        {
          "text": "WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being",
          "bbox": [
            484.0,
            1179.0,
            3027.0,
            1232.0
          ],
          "confidence": 0.9941900968551636
        },
        {
          "text": "developed as biosimilars to pharmaceutical products comprising the monoclonal antibody fragment Ranibizumab and currently",
          "bbox": [
            283.0,
            1248.0,
            3023.0,
            1290.0
          ],
          "confidence": 0.9974822402000427
        },
        {
          "text": "marketed in the field of ophthalmology under the brand name Lucentis;",
          "bbox": [
            277.0,
            1307.0,
            1769.0,
            1358.0
          ],
          "confidence": 0.9990524053573608
        },
        {
          "text": "WHEREAS, Licensee is a company focused on the development and commercialization of biosimilar products; and.",
          "bbox": [
            489.0,
            1425.0,
            2842.0,
            1469.0
          ],
          "confidence": 0.9916466474533081
        },
        {
          "text": "WHEREAS, Licensee wishes to obtain an exclusive license from Bioeq for the commercialization of Ranibizumab.",
          "bbox": [
            488.0,
            1535.0,
            3025.0,
            1581.0
          ],
          "confidence": 0.994234025478363
        },
        {
          "text": "payments to Bioeq, and Bioeq is willing to grant such license subject to the terms and conditions of this Agreement..",
          "bbox": [
            277.0,
            1661.0,
            2635.0,
            1714.0
          ],
          "confidence": 0.987329363822937
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties.",
          "bbox": [
            478.0,
            1773.0,
            3029.0,
            1829.0
          ],
          "confidence": 0.9827077984809875
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            1844.0,
            781.0,
            1888.0
          ],
          "confidence": 0.9786854386329651
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ],
          "confidence": 0.9724200963973999
        },
        {
          "text": "For purposes of this Agreement, the capitalized terms used in this Agreement shall have the respective meanings set forth in this",
          "bbox": [
            279.0,
            2076.0,
            3025.0,
            2120.0
          ],
          "confidence": 0.9897709488868713
        },
        {
          "text": "Section 1 below..",
          "bbox": [
            277.0,
            2132.0,
            615.0,
            2180.0
          ],
          "confidence": 0.9753130674362183
        },
        {
          "text": "1.1",
          "bbox": [
            480.0,
            2248.0,
            558.0,
            2299.0
          ],
          "confidence": 0.8990501761436462
        },
        {
          "text": "Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership.",
          "bbox": [
            723.0,
            2251.0,
            3025.0,
            2301.0
          ],
          "confidence": 0.9961276054382324
        },
        {
          "text": "interests representing more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general",
          "bbox": [
            277.0,
            2315.0,
            3029.0,
            2365.0
          ],
          "confidence": 0.9997035264968872
        },
        {
          "text": "partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal.",
          "bbox": [
            275.0,
            2377.0,
            3027.0,
            2429.0
          ],
          "confidence": 0.9953535199165344
        },
        {
          "text": "entity; or (b) any legal entity which, at the time such determination is being made, is controlling or under common control with, such",
          "bbox": [
            279.0,
            2441.0,
            3027.0,
            2489.0
          ],
          "confidence": 0.9948627948760986
        },
        {
          "text": "Party. As used in this definition, the term \"control', whether used as a noun or verb, refers to the possession, directly or indirectly, of",
          "bbox": [
            281.0,
            2507.0,
            3030.0,
            2551.0
          ],
          "confidence": 0.9881471991539001
        },
        {
          "text": "the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting",
          "bbox": [
            277.0,
            2566.0,
            3025.0,
            2619.0
          ],
          "confidence": 0.9916120171546936
        },
        {
          "text": "securities, by contract or otherwise.",
          "bbox": [
            279.0,
            2633.0,
            1008.0,
            2675.0
          ],
          "confidence": 0.9996840953826904
        },
        {
          "text": "1.2",
          "bbox": [
            480.0,
            2745.0,
            560.0,
            2796.0
          ],
          "confidence": 0.9998887181282043
        },
        {
          "text": "Agreement shall have the meaning ascribed to it in the introductory paragraph above..",
          "bbox": [
            721.0,
            2748.0,
            2474.0,
            2800.0
          ],
          "confidence": 0.9874227046966553
        },
        {
          "text": "1.3",
          "bbox": [
            478.0,
            2865.0,
            562.0,
            2916.0
          ],
          "confidence": 0.9999691843986511
        },
        {
          "text": "Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations..",
          "bbox": [
            721.0,
            2871.0,
            3021.0,
            2916.0
          ],
          "confidence": 0.9959530830383301
        },
        {
          "text": "including regulations of competent Regulatory Authorities and environmental laws, as amended from time to time, and the regulations.",
          "bbox": [
            281.0,
            2933.0,
            3025.0,
            2982.0
          ],
          "confidence": 0.9881802201271057
        },
        {
          "text": "promulgated thereunder, as amended from time to time..",
          "bbox": [
            281.0,
            2995.0,
            1408.0,
            3043.0
          ],
          "confidence": 0.9912785291671753
        },
        {
          "text": "1.4",
          "bbox": [
            477.0,
            3105.0,
            564.0,
            3161.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "[***]",
          "bbox": [
            712.0,
            3099.0,
            849.0,
            3166.0
          ],
          "confidence": 0.9931468963623047
        },
        {
          "text": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
          "bbox": [
            332.0,
            4437.0,
            1439.0,
            4479.0
          ],
          "confidence": 0.9927558302879333
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE AND DEVELOPMENT AGREEMENT",
          "page": 2,
          "bbox": [
            1078.0,
            409.0,
            2226.0,
            446.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1519.0,
            956.0,
            1787.0,
            1000.0
          ]
        },
        {
          "text": "1.DEFINITIONS AND INTERPRETATION",
          "page": 2,
          "bbox": [
            486.0,
            1961.0,
            1497.0,
            2003.0
          ]
        }
      ]
    }
  ]
}